Bipolar Disorder

Complex MONDO:0004985 Pathograph 5 Show in embeddings browser Psychiatric Disease

Bipolar disorder is a chronic psychiatric mood disorder characterized by recurrent episodes of mania or hypomania alternating with depression. Subtypes include bipolar I (full manic episodes), bipolar II (hypomania with major depression), and cyclothymic disorder. Its pathophysiology involves dysregulation of monoaminergic neurotransmission, mitochondrial and cellular energetics dysfunction, and disturbances of circadian and neuroplasticity signaling.

Ask OpenScientist

Ask a research question about Bipolar Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

7
Pathophys.
6
Phenotypes
1
Hypotheses
2
Gaps
5
Pathograph
5
Genes
7
Medical Actions
3
Subtypes
9
Datasets
8
References
2
Deep Research
1
Hyp. Reports
🏷

Classifications

Harrison's Part
NEUROLOGIC
◆

Subtypes

3
Bipolar I Disorder
Characterized by manic episodes, with or without depressive episodes.
Show evidence (1 reference)
PMID:31043756 SUPPORT Human Clinical
"Bipolar I disorder is strongly genetically correlated with schizophrenia, driven by psychosis"
Large GWAS shows bipolar I disorder is genetically distinguished from bipolar II by its strong correlation with schizophrenia and psychosis.
Bipolar II Disorder
Characterized by hypomanic and depressive episodes, no full mania.
Show evidence (1 reference)
PMID:31043756 SUPPORT Human Clinical
"bipolar II disorder is more strongly correlated with major depressive disorder"
GWAS genetic-correlation analysis distinguishes bipolar II disorder from bipolar I by its stronger correlation with major depressive disorder.
Cyclothymic Disorder
Chronic fluctuating mood with hypomanic and depressive symptoms.
◈

Mechanistic Hypotheses

1
Canonical Polygenic / Synaptic / Circadian Dysregulation Model
canonical_polygenic_synaptic_circadian_dysregulation_model CANONICAL
Evidence balance 7 support 1 refute 1 no evidence
Bipolar disorder is a highly heritable polygenic mood disorder in which common variants in CACNA1C, ANK3, ODZ4, and other ion-channel and synaptic genes combine with circadian/clock gene variants (CLOCK, BMAL1, NR1D1) to produce episodic mood instability. Mitochondrial dysfunction, calcium- signaling dysregulation, and altered neuroplasticity in fronto-limbic circuits (anterior cingulate, amygdala, ventral striatum) drive cycling between depressive and manic states. Lithium's mood- stabilizing efficacy (targeting GSK-3β / inositol monophosphatase / circadian amplitude), valproate's modulation of histone deacetylases, and the recurrent involvement of the dopaminergic reward system during manic episodes corroborate the polygenic-synaptic-circadian framework as the canonical model.
Retained as CANONICAL with six explicit qualifications, independently re-verified against the cited primary sources rather than the 2026 openscientist hypothesis-search report's framing (kb/hypotheses/Bipolar_Disorder/canonical_polygenic_synaptic_circadian_dysregulation_model), which finds PARTIALLY SUPPORTED. Each major pillar — common ion-channel / synaptic gene variants (CACNA1C, ANK3, ODZ4), circadian/clock variants, mitochondrial dysfunction, calcium signaling, and fronto-limbic neuroplasticity — has substantial GWAS, iPSC, animal-model, and pharmacological support, with lithium and valproate efficacy and dopaminergic mania consistent with the model. The 2025 multi-ancestry PGC4 GWAS (298 genome-wide-significant loci across 158,036 cases and 2.8 million controls, PMID:39843750) is the current largest genetic-architecture study of BD and supersedes the smaller PGC3 scan the report's genetics framing was based on. Six qualifications, each rescoped to what its cited study actually shows: (1) postmortem cortical transcriptome data (PMID:33442739) show a less-pronounced, psychosis-concentrated similarity between schizophrenia and BD gene-expression alterations — the study never tested the canonical calcium/circadian/synaptic model and did not restrict its BD sample to BD-I, so it qualifies rather than establishes that the model "best explains psychotic BD-I"; (2) the calcium-channel-blocker translational picture is a small, unresolved lead rather than a demonstrated dihydropyridine-vs-verapamil subclass effect — the decisive verapamil-to-dihydropyridine (nimodipine, then isradipine) response switch involved only two bipolar patients embedded in a 30-person mixed unipolar/bipolar refractory-affective-illness cohort (PMID:9790159), and a broader review of calcium-channel antagonist trials in BD found only limited support for efficacy (PMID:11252650); (3) lithium response pharmacogenomics implicates PI3K-Akt / focal-adhesion pathways rather than direct GSK-3β (partially reconcilable via the PI3K→Akt→GSK-3β cascade); (4) TIMELESS and RORA are circadian-gene leads from a single 2014 candidate-gene association study (353 SNPs across 21 circadian genes, meta-analysed across two internal BD cohorts, PMID:24716566), not an update established across the modern GWAS literature, so they supplement rather than displace CLOCK/BMAL1 as canonical circadian candidates; (5) the claim that BD-risk-gene-attributed structural abnormalities are shared across the psychosis spectrum conflates two weaker, separate findings — a candidate-SNP imaging study of CACNA1C/ANK3/ODZ4/SYNE1 found no risk-variant-structural association surviving multiple-testing correction (PMID:23820096), so there is no confirmed gene-attributed structural finding to generalize from, and a separate ENIGMA mega-/meta-analysis found shared cortical/subcortical abnormalities across BD, schizophrenia, major depressive disorder, and OCD generally (PMID:32646651) — a transdiagnostic pattern, not one specific to a psychosis spectrum or tied to risk-gene status; (6) critical experiments remain largely unperformed — no GSK-3β-selective inhibitor trial and no chronotherapy prevention trial from euthymia exist as of 2026, and while a modern dihydropyridine CCB trial was registered (adjunctive isradipine for bipolar depression, NCT01784666), it was terminated early for lack of enrollment (2 participants), so an adequately powered modern DHP-CCB trial remains a real gap rather than one that was never attempted.
Deep research
OpenScientist citations 49 citations 2026-05-24T15:55:47.427164
Show evidence (9 references)
PMID:21057379 SUPPORT Human Clinical
"The finding for CACNG5, taken together with the earlier implication of CACNA1C and CACNA1B, strongly suggests a key role for voltage-dependent calcium channel genes in the susceptibility to bipolar disorder and/or schizophrenia."
Existing canonical mechanism citation in the dismech knowledge base, used as the seed for the hypothesis-search deep-research run.
PMID:33442739 SUPPORT Human Clinical
"correlation analyses showed that BP subjects had similar, although less pronounced, gene expression alterations"
Postmortem cortical transcriptome comparison finds BD subjects share schizophrenia-like gene-expression alterations, but only less pronounced ones concentrated among BD subjects with psychosis. The case-control study did not test the canonical calcium/circadian/synaptic model directly and did not restrict its BD sample to BD-I, so it qualifies rather than establishes that the model "best explains psychotic BD-I."
PMID:9790159 SUPPORT Human Clinical
"two BP patients failed to maintain improvement but responded again to nimodipine and remained well with a blind transition to another dihydropyridine L-type calcium channel blocker (CCB), isradipine"
The decisive verapamil-to-dihydropyridine response switch cited for the pharmacological-subclass hypothesis involved only two bipolar patients within a 30-person mixed-diagnosis refractory-affective-illness cohort — a small case-series lead, not a demonstrated subclass effect.
+ 6 more references
?

Discussions and Knowledge Gaps

2
Do the calcium-channel susceptibility loci shared between bipolar disorder and cardiovascular disease (the established CACNA1C locus plus the pleiotropic genes TPCN1, CACNA2D2, CACNA1D, and ATP2B1) reflect a single causal calcium-signaling axis acting in both brain and cardiovascular tissue, and what is the direction of causation - does psychiatric-risk calcium-channel genotype drive cardiac electrophysiological change (e.g., QTc prolongation), or the converse?
KNOWLEDGE GAP OPEN gap_bipolar_calcium_channel_psychiatric_cardiovascular_pleiotropy
Attached to
genetic#CACNA1C
A genome-wide pairwise pleiotropy study in East Asians (Zhu et al., 2026; PMID:42436150) found shared genetic architecture across psychiatric and cardiovascular disease pairs converging on voltage-dependent calcium-channel activity, with novel pleiotropic genes (TPCN1, CACNA2D2, CACNA1D, ATP2B1) enriched in the calcium-signaling pathway alongside the established bipolar/schizophrenia locus CACNA1C. A calcium-pathway polygenic risk score was associated with prolonged QTc, and drug-target analysis implicated calcium-channel blockers and peripheral vasodilators in elevated schizophrenia risk while diuretics reduced risk across schizophrenia, bipolar disorder, and major depressive disorder. The unresolved gaps are (1) whether the same calcium-channel variants are the primary driver in brain versus a secondary consequence in cardiovascular tissue (tissue-specific direction of effect), (2) the causal direction of the calcium-genotype to QTc association, and (3) the mechanistic basis for the apparent antagonistic pleiotropy in treatment response - why L-type calcium-channel modulation may be relevant to mood episodes yet calcium-channel blockade associates with increased psychiatric risk at the population-genetic level. Resolving this bears directly on the safety of calcium-channel blockers in patients with concurrent bipolar disorder and cardiovascular disease. This is a cross-disease gap shared with the Schizophrenia, Major Depressive Disorder, and Coronary Artery Disease entries (dismech issue #6382).
Proposed experiments
Tissue-stratified Mendelian randomization of the calcium axis
Mendelian randomization study Relation: this experiment is of type this experiment type This experiment is of type Mendelian randomization study.
exp_bipolar_calcium_pleiotropy_tissue_mr
Use brain- and cardiovascular-tissue eQTLs to instrument the pleiotropic calcium-channel genes (CACNA1C, CACNA1D, CACNA2D2, ATP2B1, TPCN1) in bidirectional Mendelian randomization against bipolar disorder, schizophrenia, QTc interval, and coronary artery disease, across independent and cross-ancestry cohorts.
Decision criterion
A shared causal calcium-signaling axis would be supported if the same tissue-specific calcium-channel instruments showed concordant, directional effects on both psychiatric and cardiovascular endpoints; discordant or tissue-limited effects would instead argue for parallel, tissue-restricted mechanisms.
Show evidence (2 references)
PMID:42436150 SUPPORT Computational
"Among the novel pleiotropic genes, TPCN1, CACNA2D2, CACNA1D, and ATP2B1 are involved in voltage-dependent calcium channel activity, regulation of calcium influx, enriched in calcium-related pathway."
Genome-wide pairwise pleiotropy analysis identifies shared calcium-channel genes across psychiatric and cardiovascular disease, motivating the shared-axis question.
PMID:42436150 SUPPORT Computational
"Our findings implicated that calcium-channel blockers and peripheral vasodilators elevated SCZ risk, diuretics reduced the risks of SCZ, BIP, and MDD."
Drug-target analysis underpinning the antagonistic-pleiotropy treatment-response gap for calcium-channel modulation.
Which gene at the 3p21.1 locus carries the risk signal shared between bipolar disorder and obsessive-compulsive disorder, and is prefrontal-cortex H3K27ac histone acetylation the regulatory mechanism through which it acts - or is the ITIH3/ITIH4 prioritization an artifact of the long-range linkage disequilibrium that also spans GLT8D1, SFMBT1, NEK4 and NISCH?
KNOWLEDGE GAP OPEN gap_bip_ocd_3p21_1_effector_gene_and_h3k27ac
Attached to
genetic#ITIH3
3p21.1 is genome-wide significant in the largest GWAS of both disorders, and a 2026 cross-trait analysis (conjFDR, SMR, multi-omic colocalization) prioritizes ITIH3/ITIH4 as the shared pleiotropic signal, with SNPs colocalizing with H3K27ac haQTLs in prefrontal cortex. That result is preprint-level, statistical, and directly contradicted in its gene assignment by the only functional dissection of the region published to date: CRISPR-Cas9 editing of rs2535629, which lies inside an ITIH3 intron, changed expression of the distal genes GLT8D1, SFMBT1 and NEK4 rather than of ITIH3, and the authors attributed schizophrenia risk to SFMBT1. So an intronic ITIH3 variant is a bona fide chromatin-regulatory variant at this locus while ITIH3 is not its target - which is precisely the confound a colocalization-only analysis cannot resolve. Resolving this matters because the two candidate effectors imply different biology: ITIH3/ITIH4 are hyaluronan-binding extracellular-matrix cross-linkers (the theme already represented by the bipolar NCAN locus), whereas SFMBT1 is a polycomb-family chromatin regulator of dendritic spine density. The clinical stake is real rather than hypothetical: OCD comorbidity in bipolar disorder is associated with a measurably worse course, so a shared causal mechanism would be a tractable target.
Show evidence (3 references)
PPR:PPR1294131 Preprint · not peer-reviewed SUPPORT Computational
"where multiple SNPs (e.g., rs3774364) colocalized with H3K27ac histone acetylation QTLs in the prefrontal cortex (PP_H4 > 0.5)"
States the preprint's specific mechanistic proposal - prefrontal-cortex H3K27ac histone-acetylation QTL colocalization at the prioritized locus - which is one side of this gap.
PMID:34978167 SUPPORT In Vitro
"Interestingly, differential expression analysis of GLT8D1, SFMBT1, and NEK4 suggested that rs2535629 may confer schizophrenia risk by regulating SFMBT1 expression."
The one functional dissection of a 3p21.1 psychiatric risk variant assigns the effect of an ITIH3-intronic SNP to distal genes, concluding SFMBT1 is the mediator. PARTIAL because the disorder studied was schizophrenia, not bipolar disorder or OCD; it constrains the gene assignment at this locus rather than settling it for these two disorders.
PMID:40855518 SUPPORT Human Clinical
"BD-OCD presents a more severe and complex clinical profile, requiring specialized assessment and integrated treatment approaches."
Peer-reviewed meta-analysis of 22 studies establishing that the bipolar-OCD comorbidity carries a distinct and more severe clinical profile, which is why a shared causal locus is worth resolving.
⚙

Pathophysiology

7
Monoamine Dysregulation
Imbalances in dopamine, norepinephrine, and serotonin neurotransmission contribute to mood episodes. Elevated dopamine in mania, reduced in depression.
Dopaminergic Neuron CL:0000700 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Dopaminergic Neuron (CL:0000700). CL:0000700 is a cell type from the Cell Ontology. Serotonergic Neuron CL:0000850 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Serotonergic Neuron (CL:0000850). CL:0000850 is a cell type from the Cell Ontology. Noradrenergic Neuron CL:0008025 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Noradrenergic Neuron (CL:0008025). CL:0008025 is a cell type from the Cell Ontology.
Neurotransmitter Signaling GO:0007268 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Neurotransmitter Signaling, annotated with chemical synaptic transmission (GO:0007268). GO:0007268 is a biological process from the Gene Ontology.
Show evidence (2 references)
PMID:22363263 SUPPORT
"Activation of the dopamine receptor 2 (D2R) has been shown to stimulate the inactivation of Akt by PP2A (Beaulieu et al., 2005; Beaulieu and Gainetdinov, 2011), therefore providing a mechanism through which GPCR activation can inhibit Akt in response to extracellular signals."
Dopamine D2 receptor signaling regulates the Akt/GSK3 pathway, providing a molecular link between monoaminergic neurotransmission and mood regulation in bipolar disorder.
PMID:22363263 SUPPORT
"This mechanism of D2R signaling appears to play important roles in the regulation of locomotor behavior and sensory motor gating by dopamine (Beaulieu et al., 2004; Emamian et al., 2004). It could also contribute to the therapeutic and/or adverse effects of psychoactive drugs like amphetamines..."
The D2 receptor-mediated regulation of GSK3 activity through beta-arrestin signaling is implicated in behavioral regulation relevant to bipolar disorder and the mechanism of mood stabilizers and antipsychotics.
Mitochondrial Dysfunction
Impaired cellular energy metabolism and oxidative stress affect neuronal function. Mitochondrial abnormalities linked to mood dysregulation.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Oxidative phosphorylation GO:0006119 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal Oxidative phosphorylation (GO:0006119). GO:0006119 is a biological process from the Gene Ontology. ⚠ ABNORMAL
Show evidence (1 reference)
PMID:30285728 NO_EVIDENCE
"Psychiatric disorders (such as bipolar disorder, depression, and schizophrenia) affect the lives of millions of individuals worldwide."
This review discusses the molecular mechanisms underlying psychiatric disorders including bipolar disorder, with focus on the DISC1/GSK3 complex which regulates mitochondrial and cellular functions.
Circadian Rhythm Disruption
Disrupted sleep-wake cycles and circadian gene expression contribute to mood instability. Sleep deprivation can trigger mania.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Circadian Rhythm GO:0007623 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Circadian Rhythm (GO:0007623). GO:0007623 is a biological process from the Gene Ontology.
Show evidence (2 references)
PMID:22363263 NO_EVIDENCE
"For more than 60 years, the mood stabilizer lithium has been used alone or in combination for the treatment of bipolar disorder, schizophrenia, depression, and other mental illnesses."
This comprehensive review discusses lithium as the gold standard treatment for bipolar disorder, noting its mood-stabilizing effects through GSK3 inhibition which affects multiple cellular pathways including circadian regulation.
PMID:23919927 SUPPORT Model Organism
"these data suggest that GSK3β acts as a critical intrinsic regulator of the circadian clock and plays an important role in regulating its period in response to lithium treatment"
GSK3β haploinsufficiency lengthens circadian period in mice, mechanistically linking lithium's inhibition of GSK3β to its documented effects on circadian rhythm period and amplitude in bipolar disorder.
Neuroplasticity Alterations
Reduced BDNF and altered synaptic plasticity in mood circuits. Lithium and other mood stabilizers enhance neuroplasticity.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Synaptic Plasticity GO:0048167 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Synaptic Plasticity, annotated with regulation of synaptic plasticity (GO:0048167). GO:0048167 is a biological process from the Gene Ontology.
Show evidence (3 references)
PMID:30285728 SUPPORT
"DISC1 binds directly to GSK3 and modulates many cellular functions by negatively inhibiting GSK3 activity."
GSK3 inhibition by DISC1 and mood stabilizers like lithium is a key mechanism in bipolar disorder treatment, affecting synaptic plasticity and neuronal survival pathways.
PMID:30285728 SUPPORT
"In the present review, we will focus on the emerging roles of TRAX and its interacting proteins (including DISC1 and GSK3β) in psychiatric disorders and the potential implications for developing therapeutic interventions."
The TRAX/DISC1/GSK3β complex is implicated in psychiatric disorders including bipolar disorder and represents a therapeutic target for enhancing neuroplasticity.
PMID:21743136 SUPPORT Other
"Lithium's main mechanisms of action appear to stem from its ability to inhibit glycogen synthase kinase-3 activity and also to induce signaling mediated by brain-derived neurotrophic factor."
Lithium enhances neuroplasticity in part by inducing BDNF signaling and inhibiting GSK-3, directly complementing the reduced-BDNF pathophysiology captured in this node.
Neuroinflammation
Elevated inflammatory markers during mood episodes. Microglial activation and cytokine abnormalities contribute to pathophysiology.
Microglia CL:0000129 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Microglia, annotated with microglial cell (CL:0000129). CL:0000129 is a cell type from the Cell Ontology.
Inflammatory Response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves Inflammatory Response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology.
Show evidence (1 reference)
PMID:33958577 NO_EVIDENCE
"considering that schizophrenia is a multifactorial and highly polygenic disorder that shares many risk genes with other psychiatric illnesses including bipolar disorder, depression, intellectual disability and autism spectrum disorders, it is to be expected that these diseases may also share..."
Microglial activation and inflammatory processes are shared pathophysiological mechanisms across psychiatric disorders including bipolar disorder, contributing to synaptic dysfunction.
GSK-3β Signaling Dysregulation
Glycogen synthase kinase-3β (GSK-3β) is a constitutively active serine/threonine kinase that phosphorylates β-catenin, tau, and numerous circadian and pro-apoptotic substrates. Excess GSK-3β activity is implicated in bipolar mood instability, and GSK-3β is the principal molecular target through which lithium is thought to exert its mood-stabilizing and neuroprotective effects. Lithium inhibits GSK-3β both directly (Mg2+-competitive) and indirectly (via the Akt / β-arrestin-2 / PP2A axis), stabilizing β-catenin and mimicking canonical Wnt signaling.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Canonical Wnt Signaling GO:0060070 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Canonical Wnt Signaling, annotated with canonical Wnt signaling pathway (GO:0060070). GO:0060070 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Circadian Rhythm Disruption
Neuroplasticity Alterations
Show evidence (3 references)
PMID:8710892 SUPPORT Model Organism
"Our results suggest that lithium acts through inhibition of glycogen synthase kinase-3 beta (GSK-3 beta), which regulates cell fate determination in diverse organisms including Dictyostelium, Drosophila, and Xenopus."
Klein and Melton identified GSK-3β as a direct molecular target of lithium in developmental model organisms — the foundational evidence for the GSK-3β hypothesis of lithium's action in bipolar disorder.
PMID:8710892 SUPPORT Model Organism
"Lithium potently inhibits GSK-3 beta activity (Ki = 2 mM), but is not a general inhibitor of other protein kinases."
Lithium inhibits GSK-3β at therapeutically relevant concentrations with selectivity over other protein kinases, supporting GSK-3β as a specific target.
PMID:8994831 SUPPORT In Vitro
"Li+ treatment of Drosophila S2 cells and rat PC12 cells induces accumulation of cytoplasmic Armadillo/beta-catenin, demonstrating that Li+ can mimic Wingless signalling in intact cells, consistent with its inhibition of GSK-3."
In intact mammalian (PC12) and insect cells, lithium inhibition of GSK-3 stabilizes β-catenin and reproduces canonical Wnt (Wingless) signaling, tying GSK-3β inhibition to a defined downstream pathway.
Phosphoinositide Signaling Dysregulation
Overactivity of the phosphatidylinositol (PIP2 / IP3) second-messenger cycle is implicated in bipolar mood instability (the "inositol depletion hypothesis"). The cycle regenerates free myo-inositol through inositol monophosphatase (IMPase) and inositol polyphosphate 1-phosphatase; lithium uncompetitively inhibits these Mg2+-dependent phosphatases, depleting free inositol and dampening the overactive signaling — a therapeutic target shared with valproate and carbamazepine. (The disease-state direction shown here is the overactive baseline; lithium's opposing, inhibitory action is captured on the Lithium treatment's target_mechanisms edge.)
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Inositol Phosphate Metabolism GO:0043647 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Inositol Phosphate Metabolism, annotated with inositol phosphate metabolic process (GO:0043647). GO:0043647 is a biological process from the Gene Ontology. ↑ INCREASED Phosphatidylinositol-Mediated Signaling GO:0048015 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Phosphatidylinositol-Mediated Signaling (GO:0048015). GO:0048015 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (3 references)
PMID:12015604 SUPPORT Model Organism
"Inositol, however, reverses the effects of the drugs on growth cones, thus implicating inositol depletion in their action."
Williams et al. showed that lithium, valproate, and carbamazepine converge on inositol depletion — exogenous inositol rescues their shared cellular effect, direct evidence for the inositol-depletion mechanism.
PMID:12015604 SUPPORT Model Organism
"Berridge and colleagues suggested that inositol depletion may be the way that lithium works in bipolar affective disorder, but others have suggested that glycogen synthase kinase (GSK3) may be the relevant target."
Frames the two leading molecular hypotheses of lithium action — inositol depletion versus GSK-3 inhibition — both of which are curated as distinct pathophysiology nodes in this entry.
PMID:21743136 SUPPORT Other
"By inhibiting the activity of phosphoinositol phosphatases, it decreases levels of inositol 1,4,5-trisphosphate, a process recently identified as a novel mechanism for inducing autophagy."
Lithium inhibition of inositol phosphatases lowers IP3 and links inositol depletion to autophagy induction, a downstream neuroprotective consequence.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Bipolar Disorder Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

6
Manic Episodes VERY_FREQUENT Psychiatric HP:0100754 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Mania (HP:0100754). HP:0100754 is a phenotype from the Human Phenotype Ontology.
Elevated mood, decreased sleep, increased activity
Depressive Episodes VERY_FREQUENT Psychiatric HP:0000716 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Depression (HP:0000716). HP:0000716 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:26388529 SUPPORT Human Clinical
"onset is most commonly a depressive episode and looks similar to unipolar depression"
Depressive episodes are the most common presenting mood state in bipolar disorder, frequently mimicking unipolar major depression.
Sleep Disturbance VERY_FREQUENT Psychiatric HP:0002360 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Sleep Disturbance (HP:0002360). HP:0002360 is a phenotype from the Human Phenotype Ontology.
Decreased need for sleep in mania, insomnia or hypersomnia in depression
Psychosis OCCASIONAL Psychiatric HP:0000709 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Psychosis (HP:0000709). HP:0000709 is a phenotype from the Human Phenotype Ontology.
Can occur in severe mania or depression
Anxiety FREQUENT Psychiatric HP:0000739 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anxiety (HP:0000739). HP:0000739 is a phenotype from the Human Phenotype Ontology.
Cognitive Impairment FREQUENT Neurological HP:0100543 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cognitive Impairment (HP:0100543). HP:0100543 is a phenotype from the Human Phenotype Ontology.
Executive function, attention deficits
Show evidence (1 reference)
PMID:23846857 SUPPORT
"All proband groups showed lower psychosocial functioning than the relatives or comparison group. On average, schizophrenia probands showed more symptoms and lower psychosocial functioning than probands with psychotic bipolar disorder, but there was considerable overlap in clinical manifestations."
The B-SNIP study demonstrates that cognitive and psychosocial impairment is a consistent feature across psychotic disorders including bipolar disorder, though with varying severity.
🧬

Genetic Associations

5
CACNA1C (Risk Factor)
Gene: CACNA1C hgnc:1390 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is CACNA1C (hgnc:1390). hgnc:1390 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (2 references)
PMID:18711365 SUPPORT
"We also found further support for the previously reported CACNA1C (alpha 1C subunit of the L-type voltage-gated calcium channel; combined P = 7.0 x 10(-8), rs1006737)."
Landmark GWAS study providing genome-wide significant evidence that CACNA1C is a susceptibility locus for bipolar disorder, implicating calcium channel dysfunction in disease pathogenesis.
PMID:21057379 SUPPORT
"The finding for CACNG5, taken together with the earlier implication of CACNA1C and CACNA1B, strongly suggests a key role for voltage-dependent calcium channel genes in the susceptibility to bipolar disorder and/or schizophrenia."
Case-case GWAS analysis further confirms the critical role of calcium channel genes including CACNA1C in bipolar disorder susceptibility.
ANK3 (Risk Factor)
Gene: ANK3 hgnc:494 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ANK3 (hgnc:494). hgnc:494 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:18711365 SUPPORT
"To identify susceptibility loci for bipolar disorder, we tested 1.8 million variants in 4,387 cases and 6,209 controls and identified a region of strong association (rs10994336, P = 9.1 x 10(-9)) in ANK3 (ankyrin G)."
Genome-wide significant association of ANK3 with bipolar disorder in large-scale GWAS, establishing ankyrin G as a key susceptibility gene that may affect neuronal excitability and synaptic function.
ODZ4 (Risk Factor)
Show evidence (1 reference)
PMID:21926972 SUPPORT Human Clinical
"In particular, we support prior findings in CACNA1C, and now identify ODZ4 as associated with BD."
Psychiatric GWAS Consortium large-scale GWAS established genome-wide-significant association of the teneurin gene ODZ4 (TENM4) with bipolar disorder.
NCAN (Risk Factor)
Gene: NCAN hgnc:2465 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is NCAN (hgnc:2465). hgnc:2465 is a gene from the HUGO Gene Nomenclature Committee.
Show evidence (1 reference)
PMID:21353194 SUPPORT Human Clinical
"Genetic variation in the neurocan gene (NCAN) showed genome-wide significant association with BD"
GWAS with independent replication identified the extracellular-matrix glycoprotein gene NCAN (neurocan) as a genome-wide-significant bipolar disorder susceptibility locus.
ITIH3 (Risk Factor)
Gene: ITIH3 hgnc:6168 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is ITIH3 (hgnc:6168). hgnc:6168 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: SUSCEPTIBILITY
Show evidence (2 references)
PMID:34002096 SUPPORT Human Clinical
"9c 3 52626443 rs2336147 3.6 × 10−13 1.070 0.009 T/C 0.498 ITIH1 (PGC2) SCZ, CDG"
Table 1 row from the PGC bipolar disorder GWAS (41,917 cases): locus 9, index SNP rs2336147 at chr3:52,626,443 (GRCh37; 3p21.1), P = 3.6 x 10^-13, OR 1.070, named by the authors for ITIH1 and previously reported for schizophrenia and by the Cross-Disorder Group. This is the peer-reviewed genome-wide-significant bipolar association at the ITIH-cluster locus; the index SNP itself sits proximal to the ITIH genes rather than within them.
PPR:PPR1294131 Preprint · not peer-reviewed SUPPORT Computational
"ConjFDR analysis revealed 2,143 pleiotropic SNPs jointly associated with BIP and OCD, with convergent signals at the ITIH3/ITIH4 locus."
Cross-trait conjunctional-FDR analysis of bipolar disorder and OCD GWAS summary statistics converges on the ITIH3/ITIH4 locus. PARTIAL because this is a non-peer-reviewed preprint and a summary-statistics analysis: it prioritizes ITIH3/ITIH4 among the genes at 3p21.1 but does not experimentally establish either gene as the effector.
💊

Medical Actions

7
Lithium
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: lithium carbonate CHEBI:6504 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses lithium carbonate (CHEBI:6504). CHEBI:6504 is a therapeutic agent from Chemical Entities of Biological Interest.
First-line mood stabilizer, effective for mania and suicide prevention.
Mechanism Target:
INHIBITS GSK-3β Signaling Dysregulation — Lithium inhibits GSK-3β both directly (Mg2+-competitive) and indirectly (via Akt / β-arrestin-2 / PP2A), stabilizing β-catenin and mimicking canonical Wnt signaling — the principal proposed molecular basis of its mood-stabilizing effect.
Show evidence (1 reference)
PMID:8710892 SUPPORT Model Organism
"Our results suggest that lithium acts through inhibition of glycogen synthase kinase-3 beta (GSK-3 beta), which regulates cell fate determination in diverse organisms including Dictyostelium, Drosophila, and Xenopus."
Direct evidence that lithium acts by inhibiting GSK-3β.
INHIBITS Phosphoinositide Signaling Dysregulation — Lithium uncompetitively inhibits inositol monophosphatase and related phosphatases, depleting free inositol and dampening PIP2 / IP3 signaling.
Show evidence (1 reference)
PMID:12015604 SUPPORT Model Organism
"Inositol, however, reverses the effects of the drugs on growth cones, thus implicating inositol depletion in their action."
Inositol rescue implicates inositol depletion as a mechanism of lithium action.
MODULATES Circadian Rhythm Disruption — Through GSK-3β inhibition lithium lengthens circadian period and stabilizes clock-gene rhythm amplitude, addressing circadian instability in bipolar disorder.
MODULATES Neuroplasticity Alterations — Lithium induces BDNF signaling and upregulates neurotrophic/neuroprotective pathways, enhancing synaptic plasticity in fronto-limbic mood circuits.
Show evidence (3 references)
PMID:22363263 SUPPORT
"Lithium has been reported to reduce suicide rates and prevent manic episodes in individuals with bipolar disorder, major depression, or schizoaffective disorders"
Lithium is the gold standard mood stabilizer for bipolar disorder with demonstrated efficacy in preventing manic episodes and reducing suicide risk through GSK3 inhibition.
PMID:22363263 SUPPORT
"In 1996, two independent studies (Klein and Melton, 1996; Stambolic et al., 1996) of the effects of lithium on cell signaling and development have identified a direct effect of lithium on the activity of GSK3 both in vitro and in cells."
Lithium's therapeutic mechanism involves direct inhibition of GSK3 and indirect effects through the Akt/beta-arrestin pathway, providing molecular basis for its mood-stabilizing effects.
PMID:21743136 SUPPORT Other
"By inhibiting N-methyl-D-aspartate receptor-mediated calcium influx, for instance, it suppresses the calcium-dependent activation of pro-apoptotic signaling pathways."
Beyond GSK-3β and inositol depletion, lithium contributes to neuronal calcium homeostasis by limiting NMDA-receptor calcium influx and downstream pro-apoptotic signaling.
Valproate
Mood stabilizer, effective for mania.
Show evidence (1 reference)
PMID:11473107 SUPPORT In Vitro
"Valproic acid is widely used to treat epilepsy and bipolar disorder"
Establishes valproate as a mood stabilizer used in bipolar disorder and identifies histone deacetylase inhibition as a molecular mechanism of action.
Lamotrigine
Mood stabilizer, more effective for depression prevention.
Atypical Antipsychotics
Quetiapine, olanzapine, aripiprazole for mania and maintenance.
Antidepressants
Used cautiously with mood stabilizer to prevent switch to mania.
Psychotherapy
CBT, interpersonal therapy, psychoeducation.
Show evidence (1 reference)
PMID:26388529 SUPPORT Human Clinical
"the evolving pharmacological and psychological strategies in bipolar disorder is of utmost importance"
This clinical review emphasizes psychological (psychotherapeutic) strategies alongside pharmacotherapy as core to bipolar disorder management.
ECT
For severe or treatment-resistant episodes.
🌍

Environmental Factors

4
Childhood Trauma
psychological stress XCO:0001265 Experimental Conditions Ontology (XCO) Relation: this environmental factor is this exposure This environmental factor is psychological stress, annotated with stress (XCO:0001265). XCO:0001265 is an exposure from the Experimental Conditions Ontology.
Increases risk
Show evidence (1 reference)
PMID:33364762 SUPPORT Human Clinical
"individuals with BD are 2.63 times more likely to report CT compared to healthy individuals"
Review quantifies childhood trauma as a risk factor for bipolar disorder, with individuals with BD reporting childhood trauma at 2.63 times the rate of healthy individuals.
Sleep Deprivation
sleep deprivation XCO:0001069 Experimental Conditions Ontology (XCO) Relation: this environmental factor is this exposure This environmental factor is sleep deprivation, annotated with sleep restriction (XCO:0001069). XCO:0001069 is an exposure from the Experimental Conditions Ontology.
Can trigger manic episodes
Show evidence (1 reference)
PMID:10482346 SUPPORT Human Clinical
"we observed a 4.85% switch rate into mania and a 5.83% switch rate into hypomania"
Clinical trial of therapeutic sleep deprivation in 206 bipolar depressed patients measured the switch into mania (4.85%) and hypomania (5.83%), quantifying sleep loss as a trigger of manic episodes.
Substance Use
Comorbid and can trigger episodes
Show evidence (2 references)
PMID:34833474 SUPPORT Human Clinical
"Substance use disorders (SUD) are highly prevalent in bipolar disorder (BD) and significantly affect clinical outcomes"
PARTIAL: this supports the comorbidity half of the annotation and an effect on clinical course, but not the episode-triggering half. The same review notes it is still unclear why bipolar patients are at higher risk of addictive disorders, so the direction of that relationship is not settled.
PMID:27476137 SUPPORT Human Clinical
"The SUDs with the highest prevalence in BD were alcohol use (42%) followed by cannabis use (20%) and other illicit drug use (17%)"
Systematic review and meta-analysis quantifies the high prevalence of comorbid substance use disorders in bipolar disorder.
Stress
psychological stress XCO:0001265 Experimental Conditions Ontology (XCO) Relation: this environmental factor is this exposure This environmental factor is psychological stress, annotated with stress (XCO:0001265). XCO:0001265 is an exposure from the Experimental Conditions Ontology.
Life events can precipitate episodes
Show evidence (2 references)
PMID:24751308 SUPPORT Human Clinical
"Negative life events were significantly associated with both subsequent severity of mania and depressive symptoms and functional impairment"
Prospective study of 173 bipolar outpatients assessed quarterly for two years. PARTIAL because the same study found the reverse direction as well -- depressive symptoms preceded negative life events, and manic symptoms preceded positive ones -- so its own title asks whether life events are cause or consequence, and its authors state the design cannot settle that.
PMID:36940629 SUPPORT Human Clinical
"possible triggers including fasting, decreased sleep and stressful life events"
Systematic review of triggers for acute mood episodes in bipolar disorder identifies stressful life events among triggers for depressive relapse.
🔬

Biochemical Markers

3
BDNF (Decreased)
Context: Reduced in both manic and depressive episodes
Cortisol (Elevated)
Context: HPA axis dysregulation
Inflammatory Markers (Elevated)
Context: IL-6, TNF-alpha during episodes
📊

Related Datasets

9
Choroid plexus inflammation in bipolar disorder geo:GSE328018
Postmortem human choroid plexus tissue from individuals with bipolar disorder and matched controls was analyzed using cytokine protein arrays and bulk RNA sequencing to characterize immune and barrier-related alterations. The study identifies increased pro-inflammatory signaling and reduced trophic/supportive pathways, implicating the choroid plexus as a neuroimmune interface in bipolar disorder.
human BULK RNA SEQ n=23
PMID:41980683
Identified by GEO DataSets index search for Bipolar Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
Single-nucleus RNA sequencing in the post-mortem thamaus and cortex in bipolar disorder geo:GSE306819
We performed high-throughput single-nucleus RNA sequencing (snRNA-seq) using the 10x Genomics Chromium platform on archived postmortem thalamus and frontal cortex (BA10) tissues from patients with bipolar disorder and control subjects to identify cell type–specific differentially expressed genes and compositional changes.
human SINGLE CELL RNA SEQ n=82
PMID:41501055
Identified by GEO DataSets index search for Bipolar Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
Differential effects of lithium on metabolic dysfunction in astrocytes derived from bipolar disorder patients geo:GSE241671
Metabolic alterations have been observed in the brains of patients with bipolar disorder (BD), a neuropsychiatric disorder characterized by biphasic mood episodes of mania and depression. However, the specific contributions of glial cells to these metabolic changes in BD patients remain largely unknown and have not been extensively studied. Here, we investigate the metabolic characteristics of induced astrocytes (iAstrocytes) derived from induced pluripotent stem cells of BD patients and their responses to lithium treatment. The gene expression profiles of iAstrocytes from BD patients (BD iAstrocytes) indicate dysregulation of metabolic processes in BD iAstrocytes.
human BULK RNA SEQ n=30
PMID:40847005
Identified by GEO DataSets index search for Bipolar Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
WTCCC case-control study for Bipolar Disorder ega:EGAS00000000001
WTCCC genome-wide case-control association study for Bipolar disorder (BD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Bipolar Disorder"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
WTCCC case-control study for Bipolar Disorder - Combined Controls ega:EGAS00000000002
WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Bipolar Disorder"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Exome sequencing in bipolar disorder families ega:EGAS00001003085
Bipolar disorder (BD) is a major psychiatric disorder affecting around 1% of the global population. BD is characterized by recurrent manic and depressive episodes, and has an estimated heritability of around 70% Research has identified the first BD susceptibility genes. However, the underlying pathways and regulatory networks remain largely unknown. Since research has shown that the cumulative impact of common alleles with small effect appears to explain only around 25-38% of the phenotypic variance for BD, rare variants of high penetrance may also contribute to BD risk.
human
European Genome-phenome Archive study, matched because the disease is named in the study's own title ("Bipolar Disorder"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.
Bipolar disorder metabolomics analysis using FiehnLib and GMD for curation metabolomics_workbench:ST001946
Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Bipolar Disorder"). Retrieved 2026-08-02.
Dysregulation of the complement and coagulation cascade in treated schizophrenia and bipolar disorder patients massive:MSV000086425
A better understanding of the proteomic profile after bipolar disorder (BD) and schizophrenia (SCZ) treatment, through monitoring its progression, may assist the development of novel therapeutic strategies with the ability to reduce or control possible side effects. In this study, proteomics analysis employing liquid chromatography coupled to mass spectrometry (LC-MS) and bioinformatic tools were applied to identify differentially expressed proteins in serum of treated BD and SCZ patients. In total, 10 BD patients, 10 SCZ patients, and 14 healthy participants were included.
Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Bipolar Disorder"). Retrieved 2026-08-02.
Family Genomics of Bipolar Disorder dbgap:phs000866
This study examined the segregation of variants with phenotype in pedigrees harboring bipolar disorder.
Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Bipolar Disorder"). Retrieved 2026-08-02.
{ }

Source YAML

click to show 
name: Bipolar Disorder
creation_date: '2025-12-18T17:01:35Z'
description: >-
  Bipolar disorder is a chronic psychiatric mood disorder characterized by
  recurrent episodes of mania or hypomania alternating with depression. Subtypes
  include bipolar I (full manic episodes), bipolar II (hypomania with major
  depression), and cyclothymic disorder. Its pathophysiology involves
  dysregulation of monoaminergic neurotransmission, mitochondrial and cellular
  energetics dysfunction, and disturbances of circadian and neuroplasticity
  signaling.
category: Complex
parents:
- Psychiatric Disease
disease_term:
  preferred_term: bipolar disorder
  term:
    id: MONDO:0004985
    label: bipolar disorder
has_subtypes:
- name: Bipolar I Disorder
  description: Characterized by manic episodes, with or without depressive episodes.
  evidence:
  - reference: PMID:31043756
    reference_title: "Genome-wide association study identifies 30 loci associated with bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Bipolar I disorder is strongly genetically correlated with schizophrenia, driven by psychosis"
    explanation: Large GWAS shows bipolar I disorder is genetically distinguished from bipolar II by its strong correlation with schizophrenia and psychosis.
- name: Bipolar II Disorder
  description: Characterized by hypomanic and depressive episodes, no full mania.
  evidence:
  - reference: PMID:31043756
    reference_title: "Genome-wide association study identifies 30 loci associated with bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "bipolar II disorder is more strongly correlated with major depressive disorder"
    explanation: GWAS genetic-correlation analysis distinguishes bipolar II disorder from bipolar I by its stronger correlation with major depressive disorder.
- name: Cyclothymic Disorder
  description: Chronic fluctuating mood with hypomanic and depressive symptoms.
mechanistic_hypotheses:
- hypothesis_group_id: canonical_polygenic_synaptic_circadian_dysregulation_model
  hypothesis_label: Canonical Polygenic / Synaptic / Circadian Dysregulation Model
  status: CANONICAL
  description: >-
    Bipolar disorder is a highly heritable polygenic mood disorder in which common variants in CACNA1C,
    ANK3, ODZ4, and other ion-channel and synaptic genes combine with circadian/clock gene variants
    (CLOCK, BMAL1, NR1D1) to produce episodic mood instability. Mitochondrial dysfunction, calcium-
    signaling dysregulation, and altered neuroplasticity in fronto-limbic circuits (anterior cingulate,
    amygdala, ventral striatum) drive cycling between depressive and manic states. Lithium's mood-
    stabilizing efficacy (targeting GSK-3β / inositol monophosphatase / circadian amplitude),
    valproate's modulation of histone deacetylases, and the recurrent involvement of the dopaminergic
    reward system during manic episodes corroborate the polygenic-synaptic-circadian framework as the
    canonical model.
  notes: >-
    Retained as CANONICAL with six explicit
    qualifications, independently re-verified against the cited
    primary sources rather than the 2026 openscientist
    hypothesis-search report's framing
    (kb/hypotheses/Bipolar_Disorder/canonical_polygenic_synaptic_circadian_dysregulation_model),
    which finds PARTIALLY SUPPORTED. Each major pillar — common
    ion-channel / synaptic gene variants (CACNA1C, ANK3, ODZ4),
    circadian/clock variants, mitochondrial dysfunction, calcium
    signaling, and fronto-limbic neuroplasticity — has
    substantial GWAS, iPSC, animal-model, and pharmacological
    support, with lithium and valproate efficacy and dopaminergic
    mania consistent with the model. The 2025 multi-ancestry PGC4
    GWAS (298 genome-wide-significant loci across 158,036 cases
    and 2.8 million controls, PMID:39843750) is the current
    largest genetic-architecture study of BD and supersedes the
    smaller PGC3 scan the report's genetics framing was based on.
    Six qualifications, each rescoped to what its cited study
    actually shows: (1) postmortem cortical transcriptome data
    (PMID:33442739) show a less-pronounced, psychosis-concentrated
    similarity between schizophrenia and BD gene-expression
    alterations — the study never tested the canonical
    calcium/circadian/synaptic model and did not restrict its BD
    sample to BD-I, so it qualifies rather than establishes that
    the model "best explains psychotic BD-I"; (2) the
    calcium-channel-blocker translational picture is a small,
    unresolved lead rather than a demonstrated
    dihydropyridine-vs-verapamil subclass effect — the decisive
    verapamil-to-dihydropyridine (nimodipine, then isradipine)
    response switch involved only two bipolar patients embedded in
    a 30-person mixed unipolar/bipolar refractory-affective-illness
    cohort (PMID:9790159), and a broader review of calcium-channel
    antagonist trials in BD found only limited support for efficacy
    (PMID:11252650); (3) lithium response pharmacogenomics
    implicates PI3K-Akt / focal-adhesion pathways rather than direct
    GSK-3β (partially reconcilable via the PI3K→Akt→GSK-3β cascade);
    (4) TIMELESS and RORA are circadian-gene leads from a single 2014
    candidate-gene association study (353 SNPs across 21 circadian
    genes, meta-analysed across two internal BD cohorts,
    PMID:24716566), not an update established across the modern GWAS
    literature, so they supplement rather than displace CLOCK/BMAL1
    as canonical circadian candidates; (5) the claim that
    BD-risk-gene-attributed structural abnormalities are shared
    across the psychosis spectrum conflates two weaker, separate
    findings — a candidate-SNP imaging study of CACNA1C/ANK3/ODZ4/SYNE1
    found no risk-variant-structural association surviving
    multiple-testing correction (PMID:23820096), so there is no
    confirmed gene-attributed structural finding to generalize from,
    and a separate ENIGMA mega-/meta-analysis found shared
    cortical/subcortical abnormalities across BD, schizophrenia, major
    depressive disorder, and OCD generally (PMID:32646651) — a
    transdiagnostic pattern, not one specific to a psychosis spectrum
    or tied to risk-gene status; (6) critical experiments remain
    largely unperformed — no GSK-3β-selective inhibitor trial and no
    chronotherapy prevention trial from euthymia exist as of 2026, and
    while a modern dihydropyridine CCB trial was registered (adjunctive
    isradipine for bipolar depression, NCT01784666), it was terminated
    early for lack of enrollment (2 participants), so an adequately
    powered modern DHP-CCB trial remains a real gap rather than one
    that was never attempted.
  evidence:
  - reference: PMID:21057379
    reference_title: "Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The finding for CACNG5, taken together with the earlier implication of CACNA1C and CACNA1B, strongly suggests a key role for voltage-dependent calcium channel genes in the susceptibility to bipolar disorder and/or schizophrenia."
    explanation: >
      Existing canonical mechanism citation in the dismech
      knowledge base, used as the seed for the hypothesis-search
      deep-research run.
  - reference: PMID:33442739
    reference_title: "Similarities in Cortical Transcriptome Alterations Between Schizophrenia and Bipolar Disorder Are Related to the Presence of Psychosis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "correlation analyses showed that BP subjects had similar, although less pronounced, gene expression alterations"
    explanation: >
      Postmortem cortical transcriptome comparison finds BD subjects
      share schizophrenia-like gene-expression alterations, but only
      less pronounced ones concentrated among BD subjects with
      psychosis. The case-control study did not test the canonical
      calcium/circadian/synaptic model directly and did not restrict
      its BD sample to BD-I, so it qualifies rather than establishes
      that the model "best explains psychotic BD-I."
  - reference: PMID:9790159
    reference_title: "Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "two BP patients failed to maintain improvement but responded again to nimodipine and remained well with a blind transition to another dihydropyridine L-type calcium channel blocker (CCB), isradipine"
    explanation: >
      The decisive verapamil-to-dihydropyridine response switch cited
      for the pharmacological-subclass hypothesis involved only two
      bipolar patients within a 30-person mixed-diagnosis
      refractory-affective-illness cohort — a small case-series lead,
      not a demonstrated subclass effect.
  - reference: PMID:11252650
    reference_title: "Calcium channel antagonists for the treatment of bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "concluding there is presently limited support for their efficacy"
    explanation: >
      Review of calcium-channel-antagonist trials in bipolar disorder
      concludes that more recent, better-controlled studies found only
      limited support for efficacy, tempering the
      calcium-channel-blocker translational-failure claim.
  - reference: PMID:24716566
    reference_title: "Association between circadian genes, bipolar disorders and chronotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "TIMELESS and RORA genes may confer susceptibility to BD and impact on circadian"
    explanation: >
      Single 2014 candidate-gene association study (353 SNPs across 21
      circadian genes, meta-analysed across two internal BD cohorts)
      finds TIMELESS and RORA variants associated with BD. This is a
      circadian-gene lead from one study design, not a modern
      literature-wide meta-analytic replacement for CLOCK/BMAL1
      priority.
  - reference: PMID:23820096
    reference_title: "No evidence for association between bipolar disorder risk gene variants and brain structural phenotypes."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: "these risk SNPs do not explain a large proportion of the structural brain alterations in BD"
    explanation: >
      Candidate-SNP imaging study of CACNA1C, ANK3, ODZ4, and SYNE1
      found no risk-variant-structural association surviving
      multiple-testing correction, refuting the premise that structural
      brain abnormalities are attributed to BD risk genes in the first
      place.
  - reference: PMID:32646651
    reference_title: "Cross-Disorder Analysis of Brain Structural Abnormalities in Six Major Psychiatric Disorders: A Secondary Analysis of Mega- and Meta-analytical Findings From the ENIGMA Consortium."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain structural abnormalities in major depressive disorder, bipolar disorder, schizophrenia, and obsessive-compulsive disorder were highly correlated"
    explanation: >
      ENIGMA mega-/meta-analysis finds shared cortical/subcortical
      abnormality patterns across BD, schizophrenia, major depressive
      disorder, and obsessive-compulsive disorder generally — a
      transdiagnostic pattern, not one specific to a psychosis spectrum
      or tied to BD-risk-gene status.
  - reference: clinicaltrials:NCT01784666
    reference_title: "Adjunctive Isradipine for the Treatment of Bipolar Depression"
    supports: NO_EVIDENCE
    evidence_source: HUMAN_CLINICAL
    snippet: 'Isradipine or placebo (contains no active medication) will be used as an "add-on" to lithium, valproate, and/or atypical antipsychotics for individuals currently experiencing a major depressive episode.'
    explanation: >
      A modern adjunctive-isradipine (dihydropyridine L-type CCB) trial
      for bipolar depression was registered, refuting a categorical "no
      modern dihydropyridine CCB trial" claim. ClinicalTrials.gov
      records it as Terminated for lack of enrollment (2 participants),
      so an adequately powered modern DHP-CCB trial remains a real gap
      rather than one never attempted.
  - reference: PMID:39843750
    reference_title: "Genomics yields biological and phenotypic insights into bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "We analysed data from participants of European, East Asian, African American and Latino ancestries (n = 158,036 cases with bipolar disorder, 2.8 million controls)"
    explanation: >
      The 2025 multi-ancestry PGC4 GWAS (298 genome-wide-significant
      loci) is the current largest genetic-architecture study of BD,
      updating the polygenic-risk-locus evidence base beyond the
      smaller PGC3 scan the 2026 hypothesis-search report's genetics
      framing was based on.
pathophysiology:
- name: Monoamine Dysregulation
  description: >
    Imbalances in dopamine, norepinephrine, and serotonin neurotransmission
    contribute to mood episodes. Elevated dopamine in mania, reduced in
    depression.
  cell_types:
  - preferred_term: Dopaminergic Neuron
    term:
      id: CL:0000700
      label: dopaminergic neuron
  - preferred_term: Serotonergic Neuron
    term:
      id: CL:0000850
      label: serotonergic neuron
  - preferred_term: Noradrenergic Neuron
    term:
      id: CL:0008025
      label: noradrenergic neuron
  biological_processes:
  - preferred_term: Neurotransmitter Signaling
    term:
      id: GO:0007268
      label: chemical synaptic transmission
  evidence:
  - reference: PMID:22363263
    reference_title: "Inhibition of GSK3 by lithium, from single molecules to signaling networks."
    supports: SUPPORT
    snippet: "Activation of the dopamine receptor 2 (D2R) has been shown to stimulate the inactivation of Akt by PP2A (Beaulieu et al., 2005; Beaulieu and Gainetdinov, 2011), therefore providing a mechanism through which GPCR activation can inhibit Akt in response to extracellular signals."
    explanation: Dopamine D2 receptor signaling regulates the Akt/GSK3 pathway, providing a molecular link between monoaminergic neurotransmission and mood regulation in bipolar disorder.
  - reference: PMID:22363263
    reference_title: "Inhibition of GSK3 by lithium, from single molecules to signaling networks."
    supports: SUPPORT
    snippet: "This mechanism of D2R signaling appears to play important roles in the regulation of locomotor behavior and sensory motor gating by dopamine (Beaulieu et al., 2004; Emamian et al., 2004). It could also contribute to the therapeutic and/or adverse effects of psychoactive drugs like amphetamines and antpsychotics that act on dopamine neurotransmission"
    explanation: The D2 receptor-mediated regulation of GSK3 activity through beta-arrestin signaling is implicated in behavioral regulation relevant to bipolar disorder and the mechanism of mood stabilizers and antipsychotics.
- name: Mitochondrial Dysfunction
  description: >
    Impaired cellular energy metabolism and oxidative stress affect
    neuronal function. Mitochondrial abnormalities linked to mood
    dysregulation.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Oxidative phosphorylation
    term:
      id: GO:0006119
      label: oxidative phosphorylation
    modifier: ABNORMAL
  evidence:
  - reference: PMID:30285728
    reference_title: "The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions."
    supports: NO_EVIDENCE
    snippet: "Psychiatric disorders (such as bipolar disorder, depression, and schizophrenia) affect the lives of millions of individuals worldwide."
    explanation: This review discusses the molecular mechanisms underlying psychiatric disorders including bipolar disorder, with focus on the DISC1/GSK3 complex which regulates mitochondrial and cellular functions.
- name: Circadian Rhythm Disruption
  description: >
    Disrupted sleep-wake cycles and circadian gene expression
    contribute to mood instability. Sleep deprivation can trigger mania.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Circadian Rhythm
    term:
      id: GO:0007623
      label: circadian rhythm
  evidence:
  - reference: PMID:22363263
    reference_title: "Inhibition of GSK3 by lithium, from single molecules to signaling networks."
    supports: NO_EVIDENCE
    snippet: "For more than 60 years, the mood stabilizer lithium has been used alone or in combination for the treatment of bipolar disorder, schizophrenia, depression, and other mental illnesses."
    explanation: This comprehensive review discusses lithium as the gold standard treatment for bipolar disorder, noting its mood-stabilizing effects through GSK3 inhibition which affects multiple cellular pathways including circadian regulation.
  - reference: PMID:23919927
    reference_title: "Glycogen synthase kinase-3β haploinsufficiency lengthens the circadian locomotor activity period in mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "these data suggest that GSK3β acts as a critical intrinsic regulator of the circadian clock and plays an important role in regulating its period in response to lithium treatment"
    explanation: >-
      GSK3β haploinsufficiency lengthens circadian period in mice, mechanistically
      linking lithium's inhibition of GSK3β to its documented effects on circadian
      rhythm period and amplitude in bipolar disorder.
- name: Neuroplasticity Alterations
  description: >
    Reduced BDNF and altered synaptic plasticity in mood circuits.
    Lithium and other mood stabilizers enhance neuroplasticity.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Synaptic Plasticity
    term:
      id: GO:0048167
      label: regulation of synaptic plasticity
  evidence:
  - reference: PMID:30285728
    reference_title: "The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions."
    supports: SUPPORT
    snippet: "DISC1 binds directly to GSK3 and modulates many cellular functions by negatively inhibiting GSK3 activity."
    explanation: GSK3 inhibition by DISC1 and mood stabilizers like lithium is a key mechanism in bipolar disorder treatment, affecting synaptic plasticity and neuronal survival pathways.
  - reference: PMID:30285728
    reference_title: "The TRAX, DISC1, and GSK3 complex in mental disorders and therapeutic interventions."
    supports: SUPPORT
    snippet: "In the present review, we will focus on the emerging roles of TRAX and its interacting proteins (including DISC1 and GSK3β) in psychiatric disorders and the potential implications for developing therapeutic interventions."
    explanation: The TRAX/DISC1/GSK3β complex is implicated in psychiatric disorders including bipolar disorder and represents a therapeutic target for enhancing neuroplasticity.
  - reference: PMID:21743136
    reference_title: "Neuroprotective action of lithium in disorders of the central nervous system."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "Lithium's main mechanisms of action appear to stem from its ability to inhibit glycogen synthase kinase-3 activity and also to induce signaling mediated by brain-derived neurotrophic factor."
    explanation: >-
      Lithium enhances neuroplasticity in part by inducing BDNF signaling and
      inhibiting GSK-3, directly complementing the reduced-BDNF pathophysiology
      captured in this node.
- name: Neuroinflammation
  description: >
    Elevated inflammatory markers during mood episodes. Microglial
    activation and cytokine abnormalities contribute to pathophysiology.
  cell_types:
  - preferred_term: Microglia
    term:
      id: CL:0000129
      label: microglial cell
  biological_processes:
  - preferred_term: Inflammatory Response
    term:
      id: GO:0006954
      label: inflammatory response
  evidence:
  - reference: PMID:33958577
    reference_title: "Glutamate and microglia activation as a driver of dendritic apoptosis: a core pathophysiological mechanism to understand schizophrenia."
    supports: NO_EVIDENCE
    snippet: "considering that schizophrenia is a multifactorial and highly polygenic disorder that shares many risk genes with other psychiatric illnesses including bipolar disorder, depression, intellectual disability and autism spectrum disorders, it is to be expected that these diseases may also share some of these same mechanisms"
    explanation: Microglial activation and inflammatory processes are shared pathophysiological mechanisms across psychiatric disorders including bipolar disorder, contributing to synaptic dysfunction.
- name: GSK-3β Signaling Dysregulation
  description: >
    Glycogen synthase kinase-3β (GSK-3β) is a constitutively active
    serine/threonine kinase that phosphorylates β-catenin, tau, and numerous
    circadian and pro-apoptotic substrates. Excess GSK-3β activity is implicated
    in bipolar mood instability, and GSK-3β is the principal molecular target
    through which lithium is thought to exert its mood-stabilizing and
    neuroprotective effects. Lithium inhibits GSK-3β both directly
    (Mg2+-competitive) and indirectly (via the Akt / β-arrestin-2 / PP2A axis),
    stabilizing β-catenin and mimicking canonical Wnt signaling.
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Canonical Wnt Signaling
    term:
      id: GO:0060070
      label: canonical Wnt signaling pathway
    modifier: DECREASED
  evidence:
  - reference: PMID:8710892
    reference_title: "A molecular mechanism for the effect of lithium on development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our results suggest that lithium acts through inhibition of glycogen synthase kinase-3 beta (GSK-3 beta), which regulates cell fate determination in diverse organisms including Dictyostelium, Drosophila, and Xenopus."
    explanation: >-
      Klein and Melton identified GSK-3β as a direct molecular target of lithium
      in developmental model organisms — the foundational evidence for the GSK-3β
      hypothesis of lithium's action in bipolar disorder.
  - reference: PMID:8710892
    reference_title: "A molecular mechanism for the effect of lithium on development."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Lithium potently inhibits GSK-3 beta activity (Ki = 2 mM), but is not a general inhibitor of other protein kinases."
    explanation: >-
      Lithium inhibits GSK-3β at therapeutically relevant concentrations with
      selectivity over other protein kinases, supporting GSK-3β as a specific target.
  - reference: PMID:8994831
    reference_title: "Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Li+ treatment of Drosophila S2 cells and rat PC12 cells induces accumulation of cytoplasmic Armadillo/beta-catenin, demonstrating that Li+ can mimic Wingless signalling in intact cells, consistent with its inhibition of GSK-3."
    explanation: >-
      In intact mammalian (PC12) and insect cells, lithium inhibition of GSK-3
      stabilizes β-catenin and reproduces canonical Wnt (Wingless) signaling,
      tying GSK-3β inhibition to a defined downstream pathway.
  downstream:
  - target: Circadian Rhythm Disruption
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - GSK-3β phosphorylates core clock proteins, so excess GSK-3β activity
      shortens/destabilizes circadian period and amplitude (lithium's GSK-3β
      inhibition lengthens period, per the GSK3β-haploinsufficiency model).
  - target: Neuroplasticity Alterations
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    intermediate_mechanisms:
    - Excess GSK-3β activity suppresses BDNF/neurotrophic and β-catenin survival
      signaling, impairing synaptic plasticity in fronto-limbic mood circuits.
- name: Phosphoinositide Signaling Dysregulation
  description: >
    Overactivity of the phosphatidylinositol (PIP2 / IP3) second-messenger cycle
    is implicated in bipolar mood instability (the "inositol depletion
    hypothesis"). The cycle regenerates free myo-inositol through inositol
    monophosphatase (IMPase) and inositol polyphosphate 1-phosphatase; lithium
    uncompetitively inhibits these Mg2+-dependent phosphatases, depleting free
    inositol and dampening the overactive signaling — a therapeutic target
    shared with valproate and carbamazepine. (The disease-state direction shown
    here is the overactive baseline; lithium's opposing, inhibitory action is
    captured on the Lithium treatment's target_mechanisms edge.)
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Inositol Phosphate Metabolism
    term:
      id: GO:0043647
      label: inositol phosphate metabolic process
    modifier: INCREASED
  - preferred_term: Phosphatidylinositol-Mediated Signaling
    term:
      id: GO:0048015
      label: phosphatidylinositol-mediated signaling
    modifier: INCREASED
  evidence:
  - reference: PMID:12015604
    reference_title: "A common mechanism of action for three mood-stabilizing drugs."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Inositol, however, reverses the effects of the drugs on growth cones, thus implicating inositol depletion in their action."
    explanation: >-
      Williams et al. showed that lithium, valproate, and carbamazepine converge
      on inositol depletion — exogenous inositol rescues their shared cellular
      effect, direct evidence for the inositol-depletion mechanism.
  - reference: PMID:12015604
    reference_title: "A common mechanism of action for three mood-stabilizing drugs."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Berridge and colleagues suggested that inositol depletion may be the way that lithium works in bipolar affective disorder, but others have suggested that glycogen synthase kinase (GSK3) may be the relevant target."
    explanation: >-
      Frames the two leading molecular hypotheses of lithium action — inositol
      depletion versus GSK-3 inhibition — both of which are curated as distinct
      pathophysiology nodes in this entry.
  - reference: PMID:21743136
    reference_title: "Neuroprotective action of lithium in disorders of the central nervous system."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "By inhibiting the activity of phosphoinositol phosphatases, it decreases levels of inositol 1,4,5-trisphosphate, a process recently identified as a novel mechanism for inducing autophagy."
    explanation: >-
      Lithium inhibition of inositol phosphatases lowers IP3 and links inositol
      depletion to autophagy induction, a downstream neuroprotective consequence.
phenotypes:
- name: Manic Episodes
  category: Psychiatric
  frequency: VERY_FREQUENT
  diagnostic: true
  notes: Elevated mood, decreased sleep, increased activity
  phenotype_term:
    preferred_term: Mania
    term:
      id: HP:0100754
      label: Mania
- name: Depressive Episodes
  category: Psychiatric
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Depression
    term:
      id: HP:0000716
      label: Depression
  evidence:
  - reference: PMID:26388529
    reference_title: "Bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "onset is most commonly a depressive episode and looks similar to unipolar depression"
    explanation: Depressive episodes are the most common presenting mood state in bipolar disorder, frequently mimicking unipolar major depression.
- name: Sleep Disturbance
  category: Psychiatric
  frequency: VERY_FREQUENT
  notes: Decreased need for sleep in mania, insomnia or hypersomnia in depression
  phenotype_term:
    preferred_term: Sleep Disturbance
    term:
      id: HP:0002360
      label: Sleep disturbance
- name: Psychosis
  category: Psychiatric
  frequency: OCCASIONAL
  notes: Can occur in severe mania or depression
  phenotype_term:
    preferred_term: Psychosis
    term:
      id: HP:0000709
      label: Psychosis
- name: Anxiety
  category: Psychiatric
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Anxiety
    term:
      id: HP:0000739
      label: Anxiety
- name: Cognitive Impairment
  category: Neurological
  frequency: FREQUENT
  notes: Executive function, attention deficits
  phenotype_term:
    preferred_term: Cognitive Impairment
    term:
      id: HP:0100543
      label: Cognitive impairment
  evidence:
  - reference: PMID:23846857
    reference_title: "Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP)."
    supports: SUPPORT
    snippet: "All proband groups showed lower psychosocial functioning than the relatives or comparison group. On average, schizophrenia probands showed more symptoms and lower psychosocial functioning than probands with psychotic bipolar disorder, but there was considerable overlap in clinical manifestations."
    explanation: The B-SNIP study demonstrates that cognitive and psychosocial impairment is a consistent feature across psychotic disorders including bipolar disorder, though with varying severity.
biochemical:
- name: BDNF
  presence: Decreased
  context: Reduced in both manic and depressive episodes
- name: Cortisol
  presence: Elevated
  context: HPA axis dysregulation
- name: Inflammatory Markers
  presence: Elevated
  context: IL-6, TNF-alpha during episodes
genetic:
- name: CACNA1C
  gene_term:
    preferred_term: CACNA1C
    term:
      id: hgnc:1390
      label: CACNA1C
  association: Risk Factor
  notes: Calcium channel
  evidence:
  - reference: PMID:18711365
    reference_title: "Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder."
    supports: SUPPORT
    snippet: "We also found further support for the previously reported CACNA1C (alpha 1C subunit of the L-type voltage-gated calcium channel; combined P = 7.0 x 10(-8), rs1006737)."
    explanation: Landmark GWAS study providing genome-wide significant evidence that CACNA1C is a susceptibility locus for bipolar disorder, implicating calcium channel dysfunction in disease pathogenesis.
  - reference: PMID:21057379
    reference_title: "Case-case genome-wide association analysis shows markers differentially associated with schizophrenia and bipolar disorder and implicates calcium channel genes."
    supports: SUPPORT
    snippet: "The finding for CACNG5, taken together with the earlier implication of CACNA1C and CACNA1B, strongly suggests a key role for voltage-dependent calcium channel genes in the susceptibility to bipolar disorder and/or schizophrenia."
    explanation: Case-case GWAS analysis further confirms the critical role of calcium channel genes including CACNA1C in bipolar disorder susceptibility.
- name: ANK3
  gene_term:
    preferred_term: ANK3
    term:
      id: hgnc:494
      label: ANK3
  association: Risk Factor
  notes: Ankyrin-3
  evidence:
  - reference: PMID:18711365
    reference_title: "Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder."
    supports: SUPPORT
    snippet: "To identify susceptibility loci for bipolar disorder, we tested 1.8 million variants in 4,387 cases and 6,209 controls and identified a region of strong association (rs10994336, P = 9.1 x 10(-9)) in ANK3 (ankyrin G)."
    explanation: Genome-wide significant association of ANK3 with bipolar disorder in large-scale GWAS, establishing ankyrin G as a key susceptibility gene that may affect neuronal excitability and synaptic function.
- name: ODZ4
  association: Risk Factor
  evidence:
  - reference: PMID:21926972
    reference_title: "Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In particular, we support prior findings in CACNA1C, and now identify ODZ4 as associated with BD."
    explanation: Psychiatric GWAS Consortium large-scale GWAS established genome-wide-significant association of the teneurin gene ODZ4 (TENM4) with bipolar disorder.
- name: NCAN
  gene_term:
    preferred_term: NCAN
    term:
      id: hgnc:2465
      label: NCAN
  association: Risk Factor
  evidence:
  - reference: PMID:21353194
    reference_title: "Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Genetic variation in the neurocan gene (NCAN) showed genome-wide significant association with BD"
    explanation: GWAS with independent replication identified the extracellular-matrix glycoprotein gene NCAN (neurocan) as a genome-wide-significant bipolar disorder susceptibility locus.
- name: ITIH3
  gene_term:
    preferred_term: ITIH3
    term:
      id: hgnc:6168
      label: ITIH3
  association: Risk Factor
  relationship_type: SUSCEPTIBILITY
  notes: >-
    ITIH3 lies in the extended 3p21.1 psychiatric risk region (GRCh38
    chr3:52.79-52.81 Mb), immediately adjacent to ITIH1 and ITIH4 and within the
    same long-range LD block as GNL3, NEK4, GLT8D1, SFMBT1 and NISCH. Scope
    caveat: the index SNPs reported by the largest bipolar disorder GWAS are inside this
    region but not inside ITIH3 itself (rs2336147 is ~185 kb proximal to the ITIH cluster), so this
    entry records a locus-level susceptibility signal, not a demonstrated ITIH3
    coding or regulatory effect. ITIH3/ITIH4 were specifically prioritized as the
    shared bipolar-disorder/OCD pleiotropic signal by a 2026 cross-trait conjFDR
    plus SMR/colocalization analysis, which remains a non-peer-reviewed preprint;
    the effector gene at 3p21.1 is still contested (see the attached knowledge
    gap). ITIH heavy chains covalently cross-link hyaluronan in the
    extracellular matrix, which would place this locus in the same
    ECM-remodelling theme as the established bipolar NCAN (neurocan) locus.
  evidence:
  - reference: PMID:34002096
    reference_title: "Genome-wide association study of more than 40,000 bipolar disorder cases provides new insights into the underlying biology."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "9c 3 52626443 rs2336147 3.6 × 10−13 1.070 0.009 T/C 0.498 ITIH1 (PGC2) SCZ, CDG"
    explanation: >-
      Table 1 row from the PGC bipolar disorder GWAS (41,917 cases): locus 9,
      index SNP rs2336147 at chr3:52,626,443 (GRCh37; 3p21.1), P = 3.6 x 10^-13,
      OR 1.070, named by the authors for ITIH1 and previously reported for
      schizophrenia and by the Cross-Disorder Group. This is the peer-reviewed
      genome-wide-significant bipolar association at the ITIH-cluster locus; the
      index SNP itself sits proximal to the ITIH genes rather than within them.
  - reference: PPR:PPR1294131
    reference_title: "Cross-trait genomic analyses implicate the ITIH3 and ITIH4 locus in the shared genetic architecture of bipolar disorder and obsessive-compulsive disorder"
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "ConjFDR analysis revealed 2,143 pleiotropic SNPs jointly associated with BIP and OCD, with convergent signals at the ITIH3/ITIH4 locus."
    explanation: >-
      Cross-trait conjunctional-FDR analysis of bipolar disorder and OCD GWAS
      summary statistics converges on the ITIH3/ITIH4 locus. PARTIAL because
      this is a non-peer-reviewed preprint and a summary-statistics analysis: it
      prioritizes ITIH3/ITIH4 among the genes at 3p21.1 but does not
      experimentally establish either gene as the effector.
environmental:
- name: Childhood Trauma
  exposure_term:
    preferred_term: psychological stress
    term:
      id: XCO:0001265
      label: stress
  notes: Increases risk
  evidence:
  - reference: PMID:33364762
    reference_title: "The Impact of Childhood Trauma on Developing Bipolar Disorder: Current Understanding and Ensuring Continued Progress."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "individuals with BD are 2.63 times more likely to report CT compared to healthy individuals"
    explanation: Review quantifies childhood trauma as a risk factor for bipolar disorder, with individuals with BD reporting childhood trauma at 2.63 times the rate of healthy individuals.
- name: Sleep Deprivation
  exposure_term:
    preferred_term: sleep deprivation
    term:
      id: XCO:0001069
      label: sleep restriction
  notes: Can trigger manic episodes
  evidence:
  - reference: PMID:10482346
    reference_title: "Rate of switch from depression into mania after therapeutic sleep deprivation in bipolar depression."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "we observed a 4.85% switch rate into mania and a 5.83% switch rate into hypomania"
    explanation: Clinical trial of therapeutic sleep deprivation in 206 bipolar depressed patients measured the switch into mania (4.85%) and hypomania (5.83%), quantifying sleep loss as a trigger of manic episodes.
- name: Substance Use
  notes: Comorbid and can trigger episodes
  evidence:
  - reference: PMID:34833474
    reference_title: "Bipolar Disorder and Comorbid Use of Illicit Substances."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Substance use disorders (SUD) are highly prevalent in bipolar disorder (BD) and significantly affect clinical outcomes"
    explanation: "PARTIAL: this supports the comorbidity half of the annotation and an effect on clinical course, but not the episode-triggering half. The same review notes it is still unclear why bipolar patients are at higher risk of addictive disorders, so the direction of that relationship is not settled."
  - reference: PMID:27476137
    reference_title: "Prevalence of comorbid bipolar and substance use disorders in clinical settings, 1990-2015: Systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The SUDs with the highest prevalence in BD were alcohol use (42%) followed by cannabis use (20%) and other illicit drug use (17%)"
    explanation: Systematic review and meta-analysis quantifies the high prevalence of comorbid substance use disorders in bipolar disorder.
- name: Stress
  exposure_term:
    preferred_term: psychological stress
    term:
      id: XCO:0001265
      label: stress
  notes: Life events can precipitate episodes
  evidence:
  - reference: PMID:24751308
    reference_title: "Stressful life events in bipolar I and II disorder: cause or consequence of mood symptoms?"
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Negative life events were significantly associated with both subsequent severity of mania and depressive symptoms and functional impairment"
    explanation: "Prospective study of 173 bipolar outpatients assessed quarterly for two years. PARTIAL because the same study found the reverse direction as well -- depressive symptoms preceded negative life events, and manic symptoms preceded positive ones -- so its own title asks whether life events are cause or consequence, and its authors state the design cannot settle that."
  - reference: PMID:36940629
    reference_title: "Triggers for acute mood episodes in bipolar disorder: A systematic review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "possible triggers including fasting, decreased sleep and stressful life events"
    explanation: Systematic review of triggers for acute mood episodes in bipolar disorder identifies stressful life events among triggers for depressive relapse.
treatments:
- name: Lithium
  description: First-line mood stabilizer, effective for mania and suicide prevention.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: lithium carbonate
      term:
        id: CHEBI:6504
        label: lithium carbonate
  target_mechanisms:
  - target: GSK-3β Signaling Dysregulation
    treatment_effect: INHIBITS
    description: >-
      Lithium inhibits GSK-3β both directly (Mg2+-competitive) and indirectly
      (via Akt / β-arrestin-2 / PP2A), stabilizing β-catenin and mimicking
      canonical Wnt signaling — the principal proposed molecular basis of its
      mood-stabilizing effect.
    evidence:
    - reference: PMID:8710892
      reference_title: "A molecular mechanism for the effect of lithium on development."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Our results suggest that lithium acts through inhibition of glycogen synthase kinase-3 beta (GSK-3 beta), which regulates cell fate determination in diverse organisms including Dictyostelium, Drosophila, and Xenopus."
      explanation: Direct evidence that lithium acts by inhibiting GSK-3β.
  - target: Phosphoinositide Signaling Dysregulation
    treatment_effect: INHIBITS
    description: >-
      Lithium uncompetitively inhibits inositol monophosphatase and related
      phosphatases, depleting free inositol and dampening PIP2 / IP3 signaling.
    evidence:
    - reference: PMID:12015604
      reference_title: "A common mechanism of action for three mood-stabilizing drugs."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Inositol, however, reverses the effects of the drugs on growth cones, thus implicating inositol depletion in their action."
      explanation: Inositol rescue implicates inositol depletion as a mechanism of lithium action.
  - target: Circadian Rhythm Disruption
    treatment_effect: MODULATES
    description: >-
      Through GSK-3β inhibition lithium lengthens circadian period and stabilizes
      clock-gene rhythm amplitude, addressing circadian instability in bipolar disorder.
  - target: Neuroplasticity Alterations
    treatment_effect: MODULATES
    description: >-
      Lithium induces BDNF signaling and upregulates neurotrophic/neuroprotective
      pathways, enhancing synaptic plasticity in fronto-limbic mood circuits.
  evidence:
  - reference: PMID:22363263
    reference_title: "Inhibition of GSK3 by lithium, from single molecules to signaling networks."
    supports: SUPPORT
    snippet: "Lithium has been reported to reduce suicide rates and prevent manic episodes in individuals with bipolar disorder, major depression, or schizoaffective disorders"
    explanation: Lithium is the gold standard mood stabilizer for bipolar disorder with demonstrated efficacy in preventing manic episodes and reducing suicide risk through GSK3 inhibition.
  - reference: PMID:22363263
    reference_title: "Inhibition of GSK3 by lithium, from single molecules to signaling networks."
    supports: SUPPORT
    snippet: "In 1996, two independent studies (Klein and Melton, 1996; Stambolic et al., 1996) of the effects of lithium on cell signaling and development have identified a direct effect of lithium on the activity of GSK3 both in vitro and in cells."
    explanation: Lithium's therapeutic mechanism involves direct inhibition of GSK3 and indirect effects through the Akt/beta-arrestin pathway, providing molecular basis for its mood-stabilizing effects.
  - reference: PMID:21743136
    reference_title: "Neuroprotective action of lithium in disorders of the central nervous system."
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "By inhibiting N-methyl-D-aspartate receptor-mediated calcium influx, for instance, it suppresses the calcium-dependent activation of pro-apoptotic signaling pathways."
    explanation: >-
      Beyond GSK-3β and inositol depletion, lithium contributes to neuronal
      calcium homeostasis by limiting NMDA-receptor calcium influx and downstream
      pro-apoptotic signaling.
- name: Valproate
  description: Mood stabilizer, effective for mania.
  evidence:
  - reference: PMID:11473107
    reference_title: "Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Valproic acid is widely used to treat epilepsy and bipolar disorder"
    explanation: Establishes valproate as a mood stabilizer used in bipolar disorder and identifies histone deacetylase inhibition as a molecular mechanism of action.
- name: Lamotrigine
  description: Mood stabilizer, more effective for depression prevention.
- name: Atypical Antipsychotics
  description: Quetiapine, olanzapine, aripiprazole for mania and maintenance.
- name: Antidepressants
  description: Used cautiously with mood stabilizer to prevent switch to mania.
- name: Psychotherapy
  description: CBT, interpersonal therapy, psychoeducation.
  evidence:
  - reference: PMID:26388529
    reference_title: "Bipolar disorder."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the evolving pharmacological and psychological strategies in bipolar disorder is of utmost importance"
    explanation: This clinical review emphasizes psychological (psychotherapeutic) strategies alongside pharmacotherapy as core to bipolar disorder management.
- name: ECT
  description: For severe or treatment-resistant episodes.
discussions:
- discussion_id: gap_bipolar_calcium_channel_psychiatric_cardiovascular_pleiotropy
  prompt: >-
    Do the calcium-channel susceptibility loci shared between bipolar disorder
    and cardiovascular disease (the established CACNA1C locus plus the
    pleiotropic genes TPCN1, CACNA2D2, CACNA1D, and ATP2B1) reflect a single
    causal calcium-signaling axis acting in both brain and cardiovascular
    tissue, and what is the direction of causation - does psychiatric-risk
    calcium-channel genotype drive cardiac electrophysiological change (e.g.,
    QTc prolongation), or the converse?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - genetic#CACNA1C
  rationale: >-
    A genome-wide pairwise pleiotropy study in East Asians (Zhu et al., 2026;
    PMID:42436150) found shared genetic architecture across psychiatric and
    cardiovascular disease pairs converging on voltage-dependent calcium-channel
    activity, with novel pleiotropic genes (TPCN1, CACNA2D2, CACNA1D, ATP2B1)
    enriched in the calcium-signaling pathway alongside the established
    bipolar/schizophrenia locus CACNA1C. A calcium-pathway polygenic risk score
    was associated with prolonged QTc, and drug-target analysis implicated
    calcium-channel blockers and peripheral vasodilators in elevated
    schizophrenia risk while diuretics reduced risk across schizophrenia,
    bipolar disorder, and major depressive disorder. The unresolved gaps are
    (1) whether the same calcium-channel variants are the primary driver in
    brain versus a secondary consequence in cardiovascular tissue
    (tissue-specific direction of effect), (2) the causal direction of the
    calcium-genotype to QTc association, and (3) the mechanistic basis for the
    apparent antagonistic pleiotropy in treatment response - why L-type
    calcium-channel modulation may be relevant to mood episodes yet
    calcium-channel blockade associates with increased psychiatric risk at the
    population-genetic level. Resolving this bears directly on the safety of
    calcium-channel blockers in patients with concurrent bipolar disorder and
    cardiovascular disease. This is a cross-disease gap shared with the
    Schizophrenia, Major Depressive Disorder, and Coronary Artery Disease
    entries (dismech issue #6382).
  proposed_experiments:
  - experiment_id: exp_bipolar_calcium_pleiotropy_tissue_mr
    name: Tissue-stratified Mendelian randomization of the calcium axis
    description: >-
      Use brain- and cardiovascular-tissue eQTLs to instrument the pleiotropic
      calcium-channel genes (CACNA1C, CACNA1D, CACNA2D2, ATP2B1, TPCN1) in
      bidirectional Mendelian randomization against bipolar disorder,
      schizophrenia, QTc interval, and coronary artery disease, across
      independent and cross-ancestry cohorts.
    experiment_type:
      preferred_term: Mendelian randomization study
    decision_criterion: >-
      A shared causal calcium-signaling axis would be supported if the same
      tissue-specific calcium-channel instruments showed concordant, directional
      effects on both psychiatric and cardiovascular endpoints; discordant or
      tissue-limited effects would instead argue for parallel, tissue-restricted
      mechanisms.
  evidence:
  - reference: PMID:42436150
    reference_title: "Calcium signaling pathway implicates a shared genetic basis between psychiatric and cardiovascular diseases."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Among the novel pleiotropic genes, TPCN1, CACNA2D2, CACNA1D, and ATP2B1 are involved in voltage-dependent calcium channel activity, regulation of calcium influx, enriched in calcium-related pathway."
    explanation: >-
      Genome-wide pairwise pleiotropy analysis identifies shared
      calcium-channel genes across psychiatric and cardiovascular disease,
      motivating the shared-axis question.
  - reference: PMID:42436150
    reference_title: "Calcium signaling pathway implicates a shared genetic basis between psychiatric and cardiovascular diseases."
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "Our findings implicated that calcium-channel blockers and peripheral vasodilators elevated SCZ risk, diuretics reduced the risks of SCZ, BIP, and MDD."
    explanation: >-
      Drug-target analysis underpinning the antagonistic-pleiotropy
      treatment-response gap for calcium-channel modulation.
- discussion_id: gap_bip_ocd_3p21_1_effector_gene_and_h3k27ac
  prompt: >-
    Which gene at the 3p21.1 locus carries the risk signal shared between
    bipolar disorder and obsessive-compulsive disorder, and is prefrontal-cortex
    H3K27ac histone acetylation the regulatory mechanism through which it acts -
    or is the ITIH3/ITIH4 prioritization an artifact of the long-range linkage
    disequilibrium that also spans GLT8D1, SFMBT1, NEK4 and NISCH?
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - genetic#ITIH3
  rationale: >-
    3p21.1 is genome-wide significant in the largest GWAS of both disorders, and
    a 2026 cross-trait analysis (conjFDR, SMR, multi-omic colocalization)
    prioritizes ITIH3/ITIH4 as the shared pleiotropic signal, with SNPs
    colocalizing with H3K27ac haQTLs in prefrontal cortex. That result is
    preprint-level, statistical, and directly contradicted in its gene
    assignment by the only functional dissection of the region published to
    date: CRISPR-Cas9 editing of rs2535629, which lies inside an ITIH3 intron,
    changed expression of the distal genes GLT8D1, SFMBT1 and NEK4 rather than
    of ITIH3, and the authors attributed schizophrenia risk to SFMBT1. So an
    intronic ITIH3 variant is a bona fide chromatin-regulatory variant at this
    locus while ITIH3 is not its target - which is precisely the confound a
    colocalization-only analysis cannot resolve. Resolving this matters because
    the two candidate effectors imply different biology: ITIH3/ITIH4 are
    hyaluronan-binding extracellular-matrix cross-linkers (the theme already
    represented by the bipolar NCAN locus), whereas SFMBT1 is a polycomb-family
    chromatin regulator of dendritic spine density. The clinical stake is real
    rather than hypothetical: OCD comorbidity in bipolar disorder is associated
    with a measurably worse course, so a shared causal mechanism would be a
    tractable target.
  evidence:
  - reference: PPR:PPR1294131
    reference_title: "Cross-trait genomic analyses implicate the ITIH3 and ITIH4 locus in the shared genetic architecture of bipolar disorder and obsessive-compulsive disorder"
    supports: SUPPORT
    evidence_source: COMPUTATIONAL
    snippet: "where multiple SNPs (e.g., rs3774364) colocalized with H3K27ac histone acetylation QTLs in the prefrontal cortex (PP_H4 > 0.5)"
    explanation: >-
      States the preprint's specific mechanistic proposal - prefrontal-cortex
      H3K27ac histone-acetylation QTL colocalization at the prioritized locus -
      which is one side of this gap.
  - reference: PMID:34978167
    reference_title: "Regulatory Variant rs2535629 in ITIH3 Intron Confers Schizophrenia Risk By Regulating CTCF Binding and SFMBT1 Expression."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Interestingly, differential expression analysis of GLT8D1, SFMBT1, and NEK4 suggested that rs2535629 may confer schizophrenia risk by regulating SFMBT1 expression."
    explanation: >-
      The one functional dissection of a 3p21.1 psychiatric risk variant assigns
      the effect of an ITIH3-intronic SNP to distal genes, concluding SFMBT1 is
      the mediator. PARTIAL because the disorder studied was schizophrenia, not
      bipolar disorder or OCD; it constrains the gene assignment at this locus
      rather than settling it for these two disorders.
  - reference: PMID:40855518
    reference_title: "Clinical impact of obsessive-compulsive disorder comorbidity in bipolar disorder: a systematic review and meta-analysis."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "BD-OCD presents a more severe and complex clinical profile, requiring specialized assessment and integrated treatment approaches."
    explanation: >-
      Peer-reviewed meta-analysis of 22 studies establishing that the
      bipolar-OCD comorbidity carries a distinct and more severe clinical
      profile, which is why a shared causal locus is worth resolving.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
datasets:
- accession: geo:GSE328018
  title: Choroid plexus inflammation in bipolar disorder
  description: Postmortem human choroid plexus tissue from individuals with bipolar disorder and matched controls was analyzed using cytokine protein arrays and bulk RNA sequencing to characterize immune and barrier-related alterations. The study identifies increased pro-inflammatory signaling and reduced trophic/supportive pathways, implicating the choroid plexus as a neuroimmune interface in bipolar disorder.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 23
  publication: PMID:41980683
  notes: Identified by GEO DataSets index search for Bipolar Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE306819
  title: Single-nucleus RNA sequencing in the post-mortem thamaus and cortex in bipolar disorder
  description: We performed high-throughput single-nucleus RNA sequencing (snRNA-seq) using the 10x Genomics Chromium platform on archived postmortem thalamus and frontal cortex (BA10) tissues from patients with bipolar disorder and control subjects to identify cell type–specific differentially expressed genes and compositional changes.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: SINGLE_CELL_RNA_SEQ
  sample_count: 82
  publication: PMID:41501055
  notes: Identified by GEO DataSets index search for Bipolar Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: geo:GSE241671
  title: Differential effects of lithium on metabolic dysfunction in astrocytes derived from bipolar disorder patients
  description: Metabolic alterations have been observed in the brains of patients with bipolar disorder (BD), a neuropsychiatric disorder characterized by biphasic mood episodes of mania and depression. However, the specific contributions of glial cells to these metabolic changes in BD patients remain largely unknown and have not been extensively studied. Here, we investigate the metabolic characteristics of induced astrocytes (iAstrocytes) derived from induced pluripotent stem cells of BD patients and their responses to lithium treatment. The gene expression profiles of iAstrocytes from BD patients (BD iAstrocytes) indicate dysregulation of metabolic processes in BD iAstrocytes.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  data_type: BULK_RNA_SEQ
  sample_count: 30
  publication: PMID:40847005
  notes: Identified by GEO DataSets index search for Bipolar Disorder (scripts/discover_datasets.py); accession and metadata verified against NCBI E-utilities on 2026-07-31. Title, sample count, and organism are GEO's own values.
- accession: ega:EGAS00000000001
  title: WTCCC case-control study for Bipolar Disorder
  description: WTCCC genome-wide case-control association study for Bipolar disorder (BD) using the 1958 British Birth Cohort and the UK National Blood Service collections as controls.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Bipolar Disorder"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00000000002
  title: WTCCC case-control study for Bipolar Disorder - Combined Controls
  description: WTCCC genome-wide case-control association study for Bipolar Disorder (BD) using six disease collections together with the 1958 British Birth Cohort and the UK National Blood Service collections as controls.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Bipolar Disorder"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: ega:EGAS00001003085
  title: Exome sequencing in bipolar disorder families
  description: Bipolar disorder (BD) is a major psychiatric disorder affecting around 1% of the global population. BD is characterized by recurrent manic and depressive episodes, and has an estimated heritability of around 70% Research has identified the first BD susceptibility genes. However, the underlying pathways and regulatory networks remain largely unknown. Since research has shown that the cumulative impact of common alleles with small effect appears to explain only around 25-38% of the phenotypic variance for BD, rare variants of high penetrance may also contribute to BD risk.
  organism:
    preferred_term: human
    term:
      id: NCBITaxon:9606
      label: Homo sapiens
  notes: 'European Genome-phenome Archive study, matched because the disease is named in the study''s own title ("Bipolar Disorder"); description-level mentions were not accepted. EGA study_type: Other. Controlled access -- data require a Data Access Agreement. EGA metadata retrieved 2026-08-01.'
- accession: metabolomics_workbench:ST001946
  title: Bipolar disorder metabolomics analysis using FiehnLib and GMD for curation
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from metabolomics_workbench. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Bipolar Disorder"). Retrieved 2026-08-02.
- accession: massive:MSV000086425
  title: Dysregulation of the complement and coagulation cascade in treated schizophrenia and bipolar disorder patients
  description: A better understanding of the proteomic profile after bipolar disorder (BD) and schizophrenia (SCZ) treatment, through monitoring its progression, may assist the development of novel therapeutic strategies with the ability to reduce or control possible side effects. In this study, proteomics analysis employing liquid chromatography coupled to mass spectrometry (LC-MS) and bioinformatic tools were applied to identify differentially expressed proteins in serum of treated BD and SCZ patients. In total, 10 BD patients, 10 SCZ patients, and 14 healthy participants were included.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from massive. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Bipolar Disorder"). Retrieved 2026-08-02.
- accession: dbgap:phs000866
  title: Family Genomics of Bipolar Disorder
  description:  This study examined the segregation of variants with phenotype in pedigrees harboring bipolar disorder.
  notes: Located via OmicsDI, which aggregates across omics repositories; this record comes from dbgap. Only repositories with no other discovery route in this project and with a working accession resolver are curated from OmicsDI -- GEO, ArrayExpress, PRIDE, MetaboLights and EGA hits are excluded as duplicates of dedicated passes. Matched because the disease is named in the dataset's own title ("Bipolar Disorder"). Retrieved 2026-08-02.
references:
- reference: PPR:PPR1294131
  title: "Cross-trait genomic analyses implicate the ITIH3 and ITIH4 locus in the shared genetic architecture of bipolar disorder and obsessive-compulsive disorder"
- reference: PMID:34978167
  title: "Regulatory Variant rs2535629 in ITIH3 Intron Confers Schizophrenia Risk By Regulating CTCF Binding and SFMBT1 Expression."
- reference: PMID:40855518
  title: "Clinical impact of obsessive-compulsive disorder comorbidity in bipolar disorder: a systematic review and meta-analysis."
- reference: DOI:10.1503/jpn.230112
  title: Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models
  findings: []
- reference: DOI:10.3389/fnins.2023.1228455
  title: Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder
  findings: []
- reference: DOI:10.3389/fpsyt.2024.1414776
  title: 'The genetic association between bipolar disorder and dementia: a qualitative review'
  findings: []
- reference: DOI:10.3390/biology13100787
  title: 'Codes between Poles: Linking Transcriptomic Insights into the Neurobiology of Bipolar Disorder'
  findings: []
- reference: DOI:10.3390/brainsci14121199
  title: 'Mitochondrial Dysfunction as a Biomarker of Illness State in Bipolar Disorder: A Critical Review'
  findings: []
📚

References & Deep Research

References

8
PPR:PPR1294131
Cross-trait genomic analyses implicate the ITIH3 and ITIH4 locus in the shared genetic architecture of bipolar disorder and obsessive-compulsive disorder
No top-level findings curated for this source.
PMID:34978167
Regulatory Variant rs2535629 in ITIH3 Intron Confers Schizophrenia Risk By Regulating CTCF Binding and SFMBT1 Expression.
No top-level findings curated for this source.
PMID:40855518
Clinical impact of obsessive-compulsive disorder comorbidity in bipolar disorder: a systematic review and meta-analysis.
No top-level findings curated for this source.
DOI:10.1503/jpn.230112
Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models
No top-level findings curated for this source.
DOI:10.3389/fnins.2023.1228455
Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder
No top-level findings curated for this source.
DOI:10.3389/fpsyt.2024.1414776
The genetic association between bipolar disorder and dementia: a qualitative review
No top-level findings curated for this source.
DOI:10.3390/biology13100787
Codes between Poles: Linking Transcriptomic Insights into the Neurobiology of Bipolar Disorder
No top-level findings curated for this source.
DOI:10.3390/brainsci14121199
Mitochondrial Dysfunction as a Biomarker of Illness State in Bipolar Disorder: A Critical Review
No top-level findings curated for this source.

Deep Research

2
Disorder ▸

Disorder

  • Name: Bipolar Disorder
  • Category: Complex
  • Existing deep-research providers: falcon
  • Existing evidence reference count in YAML: 18

Key Pathophysiology Nodes

  • Monoamine Dysregulation
  • Mitochondrial Dysfunction
  • Circadian Rhythm Disruption
  • Neuroplasticity Alterations
  • Neuroinflammation
  • Deep research literature mapping

Citation Inventory (for evidence mapping)

  • DOI:10.1503/jpn.230112
  • DOI:10.3389/fnins.2023.1228455
  • DOI:10.3389/fpsyt.2024.1414776
  • DOI:10.3390/biology13100787
  • DOI:10.3390/brainsci14121199
Falcon ▸
Disease Pathophysiology Research Report
Edison Scientific Literature 23 citations 2025-12-17T23:34:54.875761

Disease Pathophysiology Research Report

Target Disease - Disease Name: Bipolar Disorder - MONDO ID: MONDO_0004985 - Category: Complex

Pathophysiology description (current understanding, 2023–2024 priority) Bipolar disorder (BD) is a polygenic, neurodevelopmentally rooted disorder characterized by recurrent episodes of mania/hypomania and depression with persistent cognitive and functional burden. Convergent molecular evidence implicates dysregulation across: (i) calcium/ion channel signaling and synaptic machinery; (ii) glutamate–GABA and monoaminergic neurotransmission; (iii) immune–inflammatory cascades; (iv) mitochondrial bioenergetics and redox homeostasis; (v) circadian clock mechanisms and neurotrophic/synaptic plasticity pathways; and (vi) oligodendroglial/myelin processes impacting fronto-limbic circuits. Notably, multiple recent syntheses underscore cross-talk between these domains, providing a mechanistic basis for mood state switching, neuroprogression, and cognitive impairment (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).

Directly quoted evidence highlights mitochondrial and inflammatory abnormalities and their interplay with synaptic/circadian pathways in BD: “a larger number of smaller-sized mitochondria have been found,” with “downregulation of fusion proteins (Mfn-2, Opa-1) and upregulation of fission (Fis-1), impaired mitophagy, higher cell-free mtDNA,” and a pro-inflammatory milieu (IL-1β, IL-6, TNF-α), alongside “greater activation [of] GSK-3α/β” and “upregulated” PI3K/Akt–mTOR in mania (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). Transcriptomic integration studies emphasize synaptic vesicle release/SNARE complex perturbation, regional specificity (DLPFC, nucleus accumbens, anterior cingulate), and links to insulin/energy pathways (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 16-17, garcia2024codesbetweenpoles pages 17-19). iPSC-based reviews report “disturbances in neurodevelopmental processes, imbalance in glutamatergic–GABAergic transmission and neuromorphological alterations” (Mar 2024; https://doi.org/10.1503/jpn.230112) (perrottelli2024advancesinthe pages 1-2). Clinically, BD associates with increased dementia risk and overlapping risk genes with neurodegeneration, including CACNA1C and SCN2A; meta-analytic estimates show approximately 2–3-fold higher dementia odds in BD (published Aug 20, 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2).

1) Core Pathophysiology - Primary mechanisms - Calcium/ion channel and synaptic signaling: GWAS convergently implicate CACNA1C (L-type Ca2+ channel) and other synaptic/ion channels (e.g., SCN2A) in BD liability; transcriptomics indicate dysregulation of SNARE-mediated synaptic vesicle exocytosis and kinase/phosphoinositide pathways in prefrontal systems (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455; Sep 2024; https://doi.org/10.3390/biology13100787) (machadovieira2023noncanonicalpathwaysin pages 3-5, garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 16-17). - Neurotransmission: Evidence supports altered glutamate–GABA balance and monoaminergic systems; iPSC models show GABA–glutamate imbalance and neuromorphological changes; DRD2- and glutamate-related transcriptomic signals are regionally enriched (Mar 2024; https://doi.org/10.1503/jpn.230112; Sep 2024; https://doi.org/10.3390/biology13100787) (perrottelli2024advancesinthe pages 1-2, garcia2024codesbetweenpoles pages 16-17, garcia2024codesbetweenpoles pages 17-19). - Neuroinflammation: Pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and inflammasome signaling (e.g., NLRP3) are repeatedly implicated; anti-inflammatory trials yield mixed results, underscoring heterogeneity and the need for biomarker stratification (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455; Nov 2024; https://doi.org/10.3390/brainsci14121199) (machadovieira2023noncanonicalpathwaysin pages 3-5, gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Mitochondria, bioenergetics, oxidative stress: Structural/functional mitochondrial abnormalities, impaired mitophagy, and oxidative stress markers are repeatedly observed; PI3K/Akt–mTOR and GSK3 signaling show state-related modulation (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Circadian dysregulation: Clock gene variation and interplay with mitochondrial biogenesis/oxidative stress are noted; circadian mechanisms modulate neuronal survival and treatment response in cellular models (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Oligodendrocyte/myelination: Clinical/imaging syntheses point to white/gray matter injury and myelin-related changes as part of neuroprogression, linked to cognitive deficits (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).

  • Dysregulated molecular pathways

  • Calcium signaling and ion channel homeostasis (CACNA1C/SCN2A); Wnt/β-catenin, GSK3, PKC; PI3K/Akt–mTOR; inflammatory cytokine cascades and NLRP3; mitophagy/mitochondrial dynamics (Mfn-2/Opa1/Fis1, LC3); synaptic vesicle exocytosis/SNARE complex; insulin/IGF signaling in cortex (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455; Nov 2024; https://doi.org/10.3390/brainsci14121199; Sep 2024; https://doi.org/10.3390/biology13100787) (machadovieira2023noncanonicalpathwaysin pages 3-5, gimenezpalomo2024mitochondrialdysfunctionas pages 8-10, garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 16-17, garcia2024codesbetweenpoles pages 17-19).

  • Affected cellular processes

  • Synaptic transmission/plasticity, excitation–inhibition balance; mitochondrial fission–fusion and mitophagy; cytokine signaling and microglial reactivity; circadian transcriptional feedback loops; oligodendrocyte-mediated myelination and white matter integrity (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455; Nov 2024; https://doi.org/10.3390/brainsci14121199; Mar 2024; https://doi.org/10.1503/jpn.230112) (machadovieira2023noncanonicalpathwaysin pages 3-5, gimenezpalomo2024mitochondrialdysfunctionas pages 8-10, perrottelli2024advancesinthe pages 1-2).

2) Key Molecular Players - Genes/Proteins (HGNC) - CACNA1C (L-type CaV1.2 alpha-1 subunit): BD risk and neuropsychiatric pleiotropy; overlaps with dementia risk; calcium signaling–synaptic plasticity (Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2). - SCN2A (Nav1.2): BD–dementia overlap; neuronal excitability (Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2). - ANK3 (ankyrin-G): GWAS-implicated scaffold at AIS/nodes; synaptic/circuit stability (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - GSK3B (GSK3β): Increased activation in mania; ties to Wnt/β-catenin and mood stabilizer targets (Nov 2024; https://doi.org/10.3390/brainsci14121199; Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10, machadovieira2023noncanonicalpathwaysin pages 3-5). - DRD2 (dopamine D2 receptor): Transcriptomic and regional associations (nucleus accumbens); monoaminergic dysregulation (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 12-13). - BDNF (brain-derived neurotrophic factor): Neuroplasticity/synaptic remodeling implicated by systems reviews; interacts with dopaminergic and glutamatergic mechanisms (Sep 2024; https://doi.org/10.3390/biology13100787; Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (garcia2024codesbetweenpoles pages 17-19, machadovieira2023noncanonicalpathwaysin pages 3-5). - Mitophagy/mitochondrial dynamics proteins: OPA1, MFN2, FIS1; LC3; apoptosis regulators (BCL2↓, FAS/BAK/APAF1↑) (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10).

  • Chemical entities (CHEBI) and relevance
  • Glutamate (CHEBI:16015) and GABA (CHEBI:16865): E/I balance; cognitive/affective circuits (Mar 2024; https://doi.org/10.1503/jpn.230112) (perrottelli2024advancesinthe pages 1-2).

  • Dopamine (CHEBI:18243) and serotonin/5-HT (CHEBI:28790): DRD2, serotonergic receptors (regional/network effects) (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 16-17).

  • Cell types (CL)

  • Neuron (CL:0000540): excitatory/inhibitory neurotransmission, synaptic plasticity (Mar 2024; https://doi.org/10.1503/jpn.230112) (perrottelli2024advancesinthe pages 1-2).
  • Microglial cell (CL:0000129): cytokine production, inflammasome–mediated responses (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).
  • Astrocyte (CL:0000127): metabolic/glutamate uptake regulation; neuroinflammatory cross-talk (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).

  • Oligodendrocyte (CL:0000128): myelin integrity; white matter connectivity (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).

  • Anatomical locations (UBERON)

  • Dorsolateral prefrontal cortex, DLPFC (UBERON:0002661): synaptic/insulin-related transcriptomic signals; cognition (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 12-13).
  • Nucleus accumbens, nAcc (UBERON:0001882): dopaminergic signaling (DRD2) (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 12-13).
  • Anterior cingulate cortex, ACC (UBERON:0001872): fronto-limbic integration; inflammatory links (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 16-17).
  • Hippocampus (UBERON:0001954): volume differences modulated by lithium; memory circuits (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 17-19).

3) Biological Processes (GO) disrupted - Synaptic vesicle exocytosis and regulation of neurotransmitter secretion; long-term synaptic plasticity (GO:0016079, GO:0099177, GO:0048167) supported by SNARE-complex and neurotrophin/mTOR signaling changes (Sep 2024; https://doi.org/10.3390/biology13100787; Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (garcia2024codesbetweenpoles pages 12-13, machadovieira2023noncanonicalpathwaysin pages 3-5). - Regulation of membrane potential and calcium ion transmembrane transport (GO:0042391, GO:0070588) via CACNA1C/SCN2A dysregulation (Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2). - Inflammatory response and cytokine-mediated signaling (GO:0006954; GO:0019221) including NLRP3–IL-1β/IL-18 axis (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5). - Mitochondrial organization, mitophagy, oxidative phosphorylation, and response to oxidative stress (GO:0007005; GO:0000422; GO:0006119; GO:0006979) (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Circadian rhythm and clock gene transcription feedback loops (GO:0007623; GO:0006342 related to chromatin/cycle regulation) linking to survival pathways (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Myelination and axon ensheathment (GO:0042552; GO:0008366) with white matter connectivity consequences (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).

4) Cellular Components (GO) - Synapse, presynaptic active zone, postsynaptic density (GO:0045202; GO:0048786; GO:0014069) (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 12-13). - Mitochondrion, mitochondrial inner membrane, mitophagosome (GO:0005739; GO:0005743; GO:0000422) (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Node of Ranvier/axon initial segment (ANK3 scaffolding), myelin sheath (GO:0030674; GO:0043209) (Nov 2024; https://doi.org/10.3390/brainsci14121199; Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10, machadovieira2023noncanonicalpathwaysin pages 3-5).

5) Disease Progression - Sequence of events (hypothesis-driven): 1) Genetic predisposition (polygenic risk in calcium/ion channels and synaptic genes) and developmental perturbations alter early neural circuit maturation (Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776; Mar 2024; https://doi.org/10.1503/jpn.230112) (hirakawa2024thegeneticassociation pages 1-2, perrottelli2024advancesinthe pages 1-2). 2) Vulnerable circuits (fronto-limbic–striatal and cerebellar contributions) exhibit E/I imbalance and synaptic plasticity deficits under stressors (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455; Sep 2024; https://doi.org/10.3390/biology13100787) (machadovieira2023noncanonicalpathwaysin pages 3-5, garcia2024codesbetweenpoles pages 16-17). 3) Bioenergetic strain and oxidative stress with impaired mitophagy lead to “smaller-sized mitochondria,” apoptotic signaling, and inflammatory amplification (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). 4) Myelin/white-matter injury and synaptic dysfunction contribute to neuroprogression and cognitive decline, with epidemiologic links to later-life dementia risk (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455; Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (machadovieira2023noncanonicalpathwaysin pages 3-5, hirakawa2024thegeneticassociation pages 1-2).

  • Stages/phases: Molecular state shifts accompany mood episodes—GSK3 activation and PI3K/Akt–mTOR upregulation in mania; inflammatory cytokines detectable across phases; mitochondrial and synaptic markers vary with illness state (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10).

6) Phenotypic manifestations and mechanistic links - Core clinical phenotypes (HP terms): mania (HP:0000718), depression (HP:0000716), sleep/circadian disturbance (HP:0002360), cognitive impairment (HP:0100543). Mechanistically, E/I imbalance and synaptic plasticity failure in DLPFC–ACC–limbic networks relate to affective lability and executive/memory deficits. The increased dementia risk in BD (OR ~2.36–2.96) supports neuroprogressive processes bridging mitochondrial, inflammatory, and synaptic/myelin pathology (published Aug 20, 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2), consistent with white/gray matter involvement and inflammatory–kynurenine axes (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).

Recent developments and latest research (2023–2024 priority) - Non-canonical pathways integrating immune–mitochondrial–synaptic axes, with mixed but instructive anti-inflammatory RCT signals; emphasis on NLRP3, lipid–eicosanoid signaling, and microbiome–immune interventions (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5). - Mitochondrial dynamics/mitophagy and mood-state signaling (GSK3, PI3K/Akt–mTOR) refined as episode-linked biomarkers; circadian–mitochondrial cross-talk proposed (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Transcriptomic regionalization: DLPFC (synaptic/insulin pathways), ACC and nAcc (glutamate/dopamine genes) with SNARE complex involvement; lithium-related hippocampal plasticity (Sep 2024; https://doi.org/10.3390/biology13100787) (garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 16-17, garcia2024codesbetweenpoles pages 17-19). - iPSC models extend causal inference on neurodevelopmental deficits and E/I imbalance in BD and schizophrenia spectra (Mar 2024; https://doi.org/10.1503/jpn.230112) (perrottelli2024advancesinthe pages 1-2). - Genetic cross-disorder overlap with dementia, highlighting CACNA1C and SCN2A in BD neuroprogression and cognitive risk trajectories (Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2).

Current applications and real-world implementations - Mood stabilizers (e.g., lithium) and atypical antipsychotics act partly via neuroplasticity/PKC–GSK3 and synaptic signaling; lithium-associated hippocampal volume maintenance aligns with neurotrophic hypotheses (Sep 2024; https://doi.org/10.3390/biology13100787; Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (garcia2024codesbetweenpoles pages 17-19, machadovieira2023noncanonicalpathwaysin pages 3-5). - Anti-inflammatory strategies (minocycline, infliximab) show mixed efficacy overall but signal in biomarker-defined subgroups (e.g., childhood maltreatment), motivating stratified trials (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5). - Translational disease modeling with iPSCs/organoids enables patient-specific interrogation of synaptic, mitochondrial, and developmental phenotypes for target discovery (Mar 2024; https://doi.org/10.1503/jpn.230112) (perrottelli2024advancesinthe pages 1-2).

Expert opinions and analysis from authoritative sources - Frontiers in Neuroscience (Aug 2023) authors argue BD is best conceptualized as a systems disorder with “immune-inflammatory mechanisms,” mitochondrial threshold effects (bioenergetics/ROS/Ca2+), and synaptic/myelin consequences, requiring multimodal treatment development (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5). - Brain Sciences (Nov 2024) review synthesizes a mechanistic cascade from mitochondrial dynamics and impaired mitophagy to apoptosis and inflammatory amplification, linking to episode-specific kinase signaling (GSK3, mTOR) and circadian–mitochondrial coupling (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - J Psychiatry & Neuroscience (Mar 2024) highlights iPSC evidence for glutamate–GABA imbalance and neurodevelopmental disruptions as convergent features across BD and schizophrenia spectrum (Mar 2024; https://doi.org/10.1503/jpn.230112) (perrottelli2024advancesinthe pages 1-2).

Relevant statistics and data from recent studies - Dementia risk: Two meta-analytic estimates cited in an Aug 2024 review reported increased dementia odds in BD of OR 2.36 (95% CI 1.36–4.09) and OR 2.96 (95% CI 2.09–4.18) (Aug 20, 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (hirakawa2024thegeneticassociation pages 1-2). - Mitochondrial morphology/dynamics: “larger number of smaller-sized mitochondria” with fusion (Mfn-2/Opa-1) down and fission (Fis-1) up; increased cell-free mtDNA; mitophagy/apoptosis markers altered (Nov 2024; https://doi.org/10.3390/brainsci14121199) (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Anti-inflammatory RCTs: minocycline positive in some, null in factorial designs; infliximab ineffective overall but signals in maltreatment subgroup; meta-analyses suggest insufficient evidence for routine NSAIDs/omega-3/pioglitazone, limited single-study support for NAC (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (machadovieira2023noncanonicalpathwaysin pages 3-5).

Ontology-anchored annotations (selected examples) - Genes/Proteins (HGNC): CACNA1C; SCN2A; ANK3; GSK3B; DRD2; BDNF (hirakawa2024thegeneticassociation pages 1-2, gimenezpalomo2024mitochondrialdysfunctionas pages 8-10, machadovieira2023noncanonicalpathwaysin pages 3-5, garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 17-19). - Biological Processes (GO): synaptic vesicle exocytosis; regulation of calcium transport; cytokine-mediated signaling; mitophagy; oxidative phosphorylation; circadian rhythm; myelination (garcia2024codesbetweenpoles pages 12-13, machadovieira2023noncanonicalpathwaysin pages 3-5, gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Cellular Components (GO): synapse/PSD; mitochondrion/inner membrane; mitophagosome; myelin sheath; node of Ranvier/AIS (garcia2024codesbetweenpoles pages 12-13, gimenezpalomo2024mitochondrialdysfunctionas pages 8-10, machadovieira2023noncanonicalpathwaysin pages 3-5). - Cell types (CL): neuron; microglia; astrocyte; oligodendrocyte (perrottelli2024advancesinthe pages 1-2, machadovieira2023noncanonicalpathwaysin pages 3-5). - Anatomical Locations (UBERON): DLPFC; ACC; nucleus accumbens; hippocampus (garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 16-17, garcia2024codesbetweenpoles pages 17-19). - Chemical entities (CHEBI): glutamate; GABA; dopamine; serotonin (perrottelli2024advancesinthe pages 1-2, garcia2024codesbetweenpoles pages 12-13). - Phenotypes (HP): mania; depressive episode; cognitive impairment; sleep disturbance (hirakawa2024thegeneticassociation pages 1-2, machadovieira2023noncanonicalpathwaysin pages 3-5).

Evidence Items (selected, with URLs and dates) - Machado-Vieira et al. “Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder.” Frontiers in Neuroscience. Published Aug 2023. URL: https://doi.org/10.3389/fnins.2023.1228455 (machadovieira2023noncanonicalpathwaysin pages 3-5). - Giménez-Palomo et al. “Mitochondrial Dysfunction as a Biomarker of Illness State in Bipolar Disorder: A Critical Review.” Brain Sciences. Nov 2024. URL: https://doi.org/10.3390/brainsci14121199 (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10). - Perrottelli et al. “Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through iPSC models.” J Psychiatry & Neuroscience. Mar 2024. URL: https://doi.org/10.1503/jpn.230112 (perrottelli2024advancesinthe pages 1-2). - Garcia & Tayo. “Codes between Poles: Transcriptomic Insights…” Biology. Sep 2024. URL: https://doi.org/10.3390/biology13100787 (garcia2024codesbetweenpoles pages 16-17, garcia2024codesbetweenpoles pages 12-13, garcia2024codesbetweenpoles pages 17-19). - Hirakawa & Terao. “The genetic association between bipolar disorder and dementia.” Frontiers in Psychiatry. Aug 20, 2024. URL: https://doi.org/10.3389/fpsyt.2024.1414776 (hirakawa2024thegeneticassociation pages 1-2).

Notes and limitations - Many mechanistic domains show heterogeneity across studies. Anti-inflammatory interventions require biomarker-guided stratification; mitochondrial/synaptic markers vary by episode/state. iPSC studies, while highly informative, require standardization and deeper phenotypic anchoring (Mar 2024; https://doi.org/10.1503/jpn.230112; Aug 2023; https://doi.org/10.3389/fnins.2023.1228455) (perrottelli2024advancesinthe pages 1-2, machadovieira2023noncanonicalpathwaysin pages 3-5).

Summary BD pathophysiology reflects convergent dysregulation of calcium/ion channel–synaptic systems, glutamate–GABA and monoamines, immune–inflammatory cascades, mitochondrial/oxidative pathways, and circadian and neurotrophic plasticity, with oligodendroglial/myelin changes impairing fronto-limbic networks. State-associated kinase signaling (GSK3, PI3K/Akt–mTOR), impaired mitophagy/oxidative stress, and cytokine activation provide plausible mechanisms for mood switches and neuroprogression with measurable cognitive risk. This multi-axis model is supported by 2023–2024 evidence from genetics, transcriptomics, mitochondria-focused reviews, and iPSC studies and motivates biomarker-stratified, circuit- and pathway-targeted therapeutics (Aug 2023; https://doi.org/10.3389/fnins.2023.1228455; Nov 2024; https://doi.org/10.3390/brainsci14121199; Mar 2024; https://doi.org/10.1503/jpn.230112; Aug 2024; https://doi.org/10.3389/fpsyt.2024.1414776) (machadovieira2023noncanonicalpathwaysin pages 3-5, gimenezpalomo2024mitochondrialdysfunctionas pages 8-10, perrottelli2024advancesinthe pages 1-2, hirakawa2024thegeneticassociation pages 1-2).

References

  1. (machadovieira2023noncanonicalpathwaysin pages 3-5): Rodrigo Machado-Vieira, Alan C. Courtes, Carlos A. Zarate, Ioline D. Henter, and Husseini K. Manji. Non-canonical pathways in the pathophysiology and therapeutics of bipolar disorder. Frontiers in Neuroscience, Aug 2023. URL: https://doi.org/10.3389/fnins.2023.1228455, doi:10.3389/fnins.2023.1228455. This article has 14 citations and is from a peer-reviewed journal.

  2. (gimenezpalomo2024mitochondrialdysfunctionas pages 8-10): Anna Giménez-Palomo, Helena Andreu, Oscar de Juan, Luis Olivier, Iñaki Ochandiano, Lidia Ilzarbe, Marc Valentí, Aldo Stoppa, Cristian-Daniel Llach, Giulio Pacenza, Ana Cristina Andreazza, Michael Berk, Eduard Vieta, and Isabella Pacchiarotti. Mitochondrial dysfunction as a biomarker of illness state in bipolar disorder: a critical review. Brain Sciences, 14:1199, Nov 2024. URL: https://doi.org/10.3390/brainsci14121199, doi:10.3390/brainsci14121199. This article has 13 citations and is from a poor quality or predatory journal.

  3. (garcia2024codesbetweenpoles pages 12-13): Jon Patrick T. Garcia and Lemmuel L. Tayo. Codes between poles: linking transcriptomic insights into the neurobiology of bipolar disorder. Biology, 13:787, Sep 2024. URL: https://doi.org/10.3390/biology13100787, doi:10.3390/biology13100787. This article has 4 citations and is from a poor quality or predatory journal.

  4. (garcia2024codesbetweenpoles pages 16-17): Jon Patrick T. Garcia and Lemmuel L. Tayo. Codes between poles: linking transcriptomic insights into the neurobiology of bipolar disorder. Biology, 13:787, Sep 2024. URL: https://doi.org/10.3390/biology13100787, doi:10.3390/biology13100787. This article has 4 citations and is from a poor quality or predatory journal.

  5. (garcia2024codesbetweenpoles pages 17-19): Jon Patrick T. Garcia and Lemmuel L. Tayo. Codes between poles: linking transcriptomic insights into the neurobiology of bipolar disorder. Biology, 13:787, Sep 2024. URL: https://doi.org/10.3390/biology13100787, doi:10.3390/biology13100787. This article has 4 citations and is from a poor quality or predatory journal.

  6. (perrottelli2024advancesinthe pages 1-2): Andrea Perrottelli, Francesco Flavio Marzocchi, Edoardo Caporusso, Giulia Maria Giordano, Luigi Giuliani, Antonio Melillo, Pasquale Pezzella, Paola Bucci, Armida Mucci, and Silvana Galderisi. Advances in the understanding of the pathophysiology of schizophrenia and bipolar disorder through induced pluripotent stem cell models. Journal of Psychiatry & Neuroscience : JPN, 49:E109-E125, Mar 2024. URL: https://doi.org/10.1503/jpn.230112, doi:10.1503/jpn.230112. This article has 14 citations.

  7. (hirakawa2024thegeneticassociation pages 1-2): Hirofumi Hirakawa and Takeshi Terao. The genetic association between bipolar disorder and dementia: a qualitative review. Frontiers in Psychiatry, Aug 2024. URL: https://doi.org/10.3389/fpsyt.2024.1414776, doi:10.3389/fpsyt.2024.1414776. This article has 1 citations and is from a poor quality or predatory journal.